Salts of aza-bicyclic di-aryl ethers and pharmaceuticals thereof

ABSTRACT

The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS

This application is a National Stage of International Application No.PCT/EP2012/063712, filed Jul. 12, 2012, which is based upon and claimsthe benefit of priority from prior U.S. Provisional Patent ApplicationNo. 61/508,147, filed Jul. 15, 2011, the entire contents of all of whichare incorporated herein by reference in their entirety.

The present invention relates to salts of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane,to methods for making them or their precursors, to pharmaceuticalcompositions comprising them, and to their use as medicaments.

I. Salts of Aza-Bicyclic Di-Aryl Ethers

The compound(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane ofthe formula I

is described in WO2004/022556A1. Valuable pharmacological properties areattributed to this compound; thus it can be used as a nicotinicacetylcholine receptor alpha 7 agonist (α7-nAChR agonist) useful intherapy for disorders which respond to α7-nAChR modulation, e.g.psychiatric (e.g. schizophrenia) and/or neurodegenerative disorders(e.g. Alzheimers Disease). WO2004/022556A1 discloses(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane infree form crystallized from acetonitrile, but does not disclose anyspecific salts of said compound.(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane infree form is hygroscopic, has a low aqueous solubility and a low meltingpoint.

Selection criteria for solid forms depend on the planned indications androute(s) of administration. For a CNS-indication, such as schizophrenia,with an envisaged oral route of administration it is important to e.g.achieve a good absorption/oral bioavailability. Typically, suitablesolid forms are crystalline forms having a low hygroscopy, a highaqueous solubility, a high melting point and do not exist in multipleforms (e.g. polymorphs, solvates and/or hydrates). Further relevantparameters are safety aspects (e.g. low toxicity), stability in bulk,compatibility with excipients, pH of aqueous solution, good morphologyand easy handling.

The invention therefore provides a salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanewherein said salt is the fumarate, maleate, chloride, phosphate,succinate or malonate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane.Unless specified otherwise, said salt will be referred to hereinafter as“SALT OF THE INVENTION”.

As used herein “salt” may include hydrates and solvates.

As used herein “crystalline form” refers to a solid form of a molecule,atom and/or ion, in which its constituent atoms, molecules and/or ionsare arranged in an orderly repeating pattern extending in all threespatial dimensions.

As used herein “polymorph” refers to crystalline forms having the samechemical composition but different spatial arrangements of themolecules, atoms and/or ions forming the crystal.

As used herein “amorphous form” refers to a solid form of a molecule,atom and/or ion that is not crystalline. An amorphous solid does notdisplay a definitive X-ray diffraction pattern.

As used herein “solvate” refers to a form, e.g. a crystalline form, of amolecule, atom and/or ions that further comprises molecules of a solventor solvents incorporated into the solid structure, e.g. crystallinelattice structure. The solvent molecules in the solvate may be presentin a regular arrangement and/or a non-ordered arrangement. The solvatemay comprise either a stoichiometic or nonstoichiometric amount of thesolvent molecules. For example, a solvate with a nonstoichiometricamount of solvent molecules may result from partial loss of solvent formthe solvate. Solvates may occur as dimers or oligomers comprising morethan one molecule of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanewithin a crystalline lattice structure.

As used herein “substantially pure”, when used in reference to a solidform, means a compound, e.g. a salt (such as the mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane),having a purity greater than 90 weight %, including greater than 90, 91,92, 93, 94, 95, 96, 97, 98, and 99 weight %, and also including equal toabout 100 weight % of the compound, e.g. of the mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane,based on the weight of the solid form. The remaining material in thesolid form may comprise e.g. reaction impurities and/or processingimpurities arising from its preparation and/or—if applicable—otherform(s) of the compound. For example, a crystalline form of themono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanemay be deemed substantially pure in that it has a purity greater than 90weight %, as measured by means that are at this time known and generallyaccepted in the art, where the remaining less than 10 weight % ofmaterial comprises reaction impurities and/or processing impurities.

As used herein “mono-” in connection with salts, e.g. mono-fumaratesalts, refers to a base to acid ratio of about 1:1.

Salts

1. Fumarate Salt:

In embodiment 1, the SALT OF THE INVENTION is the fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane,e.g. the mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form. The mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form may be produced from isopropyl alcohol when oneequivalent fumaric acid is used.

The molecular formula is C₂₃H₂₆N₂O₅.

It shows good solubility in aqueous media (>30 mg/ml in water, 0.1N Hcl,and pH 6.8 buffer). It is slightly hygroscopic: Loss on drying (LOD) ofa sample was <0.03% and moisture gain was 0.5% at 85% relative humidity(RH).

Its melting point was determined by heating at 2° C./minute to be164-168.5° C. (onset) with subsequent decomposition.

It shows good stability in many buffer solutions and at various pHvalues. Also the solid-state stability is good.

The X-ray powder diffraction (XRPD) pattern of a sample preparedaccording to this method (see also Example 1) is shown in FIG. 1.Measurements were performed at a temperature of about 22° C. and anx-ray wavelength, λ, of 1.5418 Å (CuKα λ=1.5418 Å).

Summary of XRPD Pattern:

2 theta No. (deg°) Intensity 1 17.4 75.2 2 15.2 49.8 3 3.8 46.3 4 20.145.2 5 19.8 35.7 6 13.7 33.8 7 22.8 31.2 8 19.2 25.9 9 26.7 24 10 18.522.5 11 25.9 22.2 12 11.3 21.5 13 29.3 18.5 14 20.9 16.7 15 26.5 15.8 1621.8 15.7 17 30.8 9.1 18 27.5 8.4 19 7.6 8.3 20 25.1 8 21 23.2 7.6 2236.4 7.6 23 23.9 7.4 24 38.9 6.5

In one embodiment, the mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form is characterized by an XRPD pattern with at least four,more preferably five, most preferably all of the following peaks at anangle of refraction 2 theta (2θ) of 3.8, 13.7, 15.2, 17.4, 19.8 and20.1, ±0.2, respectively.

In one embodiment, the mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form is characterized by an XRPD pattern substantially thesame as the XRPD pattern shown in FIG. 1.

The term “substantially the same” with reference to X-ray diffractionpeak positions means that typical peak position and intensityvariability are taken into account. For example, one skilled in the artwill appreciate that the peak positions (2Θ) will show someinter-apparatus variability, typically as much as 0.2°. Further, oneskilled in the art will appreciate that peak intensities will showinter-apparatus variability as well as variability due to degree ofcrystallinity, preferred orientation, prepared sample surface, and otherfactors known to those skilled in the art, and should be taken asqualitative measure only.

2. Maleate Salt:

In embodiment 2, the SALT OF THE INVENTION is the maleate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane,e.g. the mono-maleate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form.

The mono-maleate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form may be produced from acetonitrile when one equivalentmaleic acid is used.

It shows good solubility in aqueous media (>30 mg/ml in water, 0.1N HCl,and pH 6.8 buffer). It is slightly hygroscopic: LOD of a sample was<0.03% and moisture gain was 0.3% at 85% RH.

Its melting point was determined by heating at 2° C./minute to be152-154° C. (onset) with subsequent decomposition.

It shows good stability in many buffer solutions and at various pHvalues. Also the solid-state stability is good.

The XRPD pattern of a sample prepared according to this method (see alsoExample 2) is shown in FIG. 2. Measurements were performed at atemperature of about 22° C. and an x-ray wavelength, λ, of 1.5418 Å(CuKα λ=1.5418 Å).

Summary of XRPD Pattern:

2 theta No. (deg°) Intensity 1 19.1 199.1 2 23.5 95.4 3 18 80.1 4 1654.2 5 12.9 46.3 6 19.9 45.4 7 12.6 45 8 16.5 34.1 9 30.5 32.1 10 28.726 11 24.9 25.6 12 31.3 25.4 13 9.5 25.1 14 25.5 23.3 15 27.9 21.7 1624.6 21.6 17 18.6 17.8 18 35 17.6 19 21.9 15.9 20 26 15.9 21 26.4 15.622 15.6 15.2 23 29.8 14.4 24 35.8 12 25 33.2 11.7 26 29.6 11.5

In one embodiment, the mono-maleate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form is characterized by an XRPD pattern with at least four,more preferably five, most preferably all of the following peaks at anangle of refraction 2 theta (2θ) of 12.9, 16.0, 18.0, 19.1, 19.9 and23.5, ±0.2, respectively.

In one embodiment, the mono-maleate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form is characterized by an XRPD pattern substantially thesame as the XRPD pattern shown in FIG. 2.

3. Hydrochloride Salt:

In embodiment 3, the SALT OF THE INVENTION is the hydrochloride salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane,e.g. the mono-hydrochloride salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form. The mono-hydrochloride salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form may be produced directly from a synthesis mixture byadding hydrochloric acid.

It shows good solubility in aqueous media (>30 mg/ml).

It is hygroscopic and may form mono- and/or di-hydrates depending onhumidity level; when tested, LOD of a sample was about 5% and thisamount of water was retained under normal conditions (i.e. at about40-50% RH). Theoretically, an amount of 5.2% water correlates to 1 watermolecule per salt molecule. Moisture gain was about 5% at 85% RH—whichwould correlate with 2 water molecules per salt molecule.

Its melting point was determined by heating at 2° C./minute to be 240°C. (onset) with subsequent decomposition.

The XRPD pattern of a sample prepared directly from a synthesis mixture(e.g. see Example 3.1.) is shown in FIG. 3. Measurements were performedat a temperature of about 22° C. and an x-ray wavelength, λ, of 1.5418 Å(CuKα λ=1.5418 Å).

Summary of XRPD Pattern:

2 theta No. (deg°) Intensity 1 20.8 125.1 2 7.3 81.4 3 17.2 50.9 4 11.646.6 5 18.4 46.3 6 31.1 34.8 7 26.7 34.3 8 19.7 22.7 9 14.6 20.7 10 23.519.9 11 16.3 16.6 12 28.8 12 13 27.2 11.4 14 25 10.9 15 22.9 10.9 1613.5 8.9

In one embodiment, the mono-hydrochloride salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form is characterized by an XRPD pattern with at least four,more preferably five, most preferably all of the following peaks at anangle of refraction 2 theta (2θ) of 7.3, 11.6, 17.2, 18.4, 20.8 and31.1, ±0.2, respectively.

In one embodiment, the mono-hydrochloride salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form is characterized by an XRPD pattern substantially thesame as the XRPD pattern shown in FIG. 3.

4. Phosphate Salt:

In embodiment 4, the SALT OF THE INVENTION is the phosphate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane,e.g. the mono-phosphate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form.

It was discovered, that said phosphate salt exists in more than onesolid form.

4.1. Form A of the Mono-Phosphate Salt:

A mono-phosphate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form may be produced from ethanol when one equivalentphosphoric acid is used.

The XRPD pattern of a sample prepared according to this method (see alsoExample 4.1) is shown in FIG. 4A. Measurements were performed at atemperature of about 22° C. and an x-ray wavelength, λ, of 1.5418 Å(CuKα λ=1.5418 Å).

Summary of XRPD Pattern:

2 theta No. (deg°) Intensity 1 17.7 76.3 2 14.3 76 3 18.2 75.1 4 19.764.9 5 16.5 56.3 6 4.7 46.6 7 20 40.2 8 21.8 29.7 9 26 24.4 10 18.8 20.711 12.2 16.3 12 30.4 13.8 13 25.7 13.2 14 22.8 12.8 15 22.5 12.6 16 29.412.5 17 35 10.6

In one embodiment, the mono-phosphate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form is characterized by an XRPD pattern with at least four,more preferably five, most preferably all of the following peaks at anangle of refraction 2 theta (2θ) of 4.7, 14.3, 16.5, 17.7, 18.2 and19.7, ±0.2, respectively.

In one embodiment, the mono-phosphate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form is characterized by an XRPD pattern substantially thesame as the XRPD pattern shown in FIG. 4A.

Form A of the mono-phosphate salt shows good solubility in aqueous media(>30 mg/ml). It is slightly hygroscopic: when tested, LOD of a samplewas about 0.5% and moisture gain was 0.2% at 85% RH.

Its melting/decomposition point was determined by heating at 2°C./minute to be about 222° C.

4.2. Form B of the Phosphate Salt:

Another form of the phosphate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form (Form B of the phosphate salt) was found as describedin the Examples section (see Example 4.2). The associated XRPD patternis shown in FIG. 4B.

Summary of XRPD Pattern:

2 theta No. (deg°) Intensity 1 14.5 131.9 2 14 106.9 3 14.2 101.1 4 15.662.4 5 19.7 51.5 6 19.3 42.3 7 13.1 36 8 16.8 34.2 9 20 32.6 10 18 30.411 12.4 29.2 12 22.6 24.4 13 16.4 20.7 14 4.2 19.3 15 10.4 18 16 23 17.817 11.5 17.4 18 15.1 15.6 19 32.6 14.2 20 12 13.7 21 20.7 13.6 22 24.712.9 23 21 12.7 24 23.5 12.5 25 25.8 11.2 26 9 11.1 27 9.6 10.8 28 30.59.6 29 25.2 9.4 30 33.8 9.3 31 27.1 9.1 32 33.3 8.8 33 30.1 8 34 7.8 835 31.5 7.5 36 8.3 7.2 37 29.6 7.2 38 26.7 6.8 39 29.1 6.4 40 7.1 6.24.3. Form C of the Phosphate Salt:

Another form of the phosphate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form (Form C of the phosphate salt) was found as describedin the Examples section (see Example 4.3). The associated XRPD patternis shown in FIG. 4C.

Summary of XRPD Pattern:

2 theta No. (deg°) Intensity 1 4.6 155.5 2 14.9 68.8 3 16.9 54.8 4 17.750.4 5 19.9 47.6 6 18.6 44.6 7 13.9 44.5 8 21.6 37.5 9 20.2 36.2 10 25.832.8 11 18 22.9 12 30.1 17.4 13 22.7 16.2 14 29.4 16 15 12.1 11.1 16 7.29.75. Succinate Salt:

In embodiment 5, the SALT OF THE INVENTION is the succinate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane,e.g. the mono-succinate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form.

It was discovered, that said mono-succinate salt exists in more than onesolid form.

5.1 Form A of the Mono-Succinate Salt

A mono-succinate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form may be produced from ethanol when one equivalentsuccinic acid is used.

The XRPD pattern of a sample prepared according to this method (see alsoExample 5) is shown in FIG. 5A. Measurements were performed at atemperature of about 22° C. and an x-ray wavelength, λ, of 1.5418 Å(CuKα λ=1.5418 Å).

Summary of XRPD Pattern:

2 theta No. (deg°) Intensity 1 17.4 178.5 2 19.4 161.1 3 10.7 45.4 415.2 38.7 5 15.8 31.5 6 23.7 28.2 7 13.3 28.1 8 21.8 24.8 9 18.4 23.7 1012.9 19.5 11 14.8 17.1 12 9.2 15.2 13 29.1 15 14 23 14.6 15 6.5 14.6 1625.3 13.1 17 30 12.5 18 24.6 11.4 19 32.9 11

In one embodiment, the mono-succinate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form is characterized by an XRPD pattern with at least four,more preferably five, most preferably all of the following peaks at anangle of refraction 2 theta (2θ) of 10.7, 15.2, 15.8, 17.4, 19.4 and23.7, ±0.2, respectively.

In one embodiment, the mono-succinate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form is characterized by an XRPD pattern substantially thesame as the XRPD pattern shown in FIG. 5A.

Form A of the mono-succinate salt shows good solubility in aqueous media(2-15 mg/ml). It is considered to be a mono-hydrate: when tested, LOD ofa sample was about 4.5%. Theoretically, an amount of 4.1% watercorrelates to 1 water molecule per salt molecule. Moisture gain was 0.3%at 85% RH.

Its melting point was determined by heating at 2° C./minute to be 113°C. (onset) with subsequent decomposition.

5.2. Form B of the Mono-Succinate Salt:

Another form of the succinate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form (Form B of the mono-succinate salt) was found asdescribed in the Examples section (see Example 5.2). The associated XRPDpattern is shown in FIG. 5B.

Summary of XRPD Pattern:

2 theta No. (deg°) Intensity 1 7.7 2279 2 18.1 1417 3 3.8 909 4 20.8 9015 17 816 6 22.3 765 7 15.5 639 8 23.9 578 9 24 564 10 19.4 463 11 16.9462 12 25.5 423 13 18.8 418 14 21.9 367 15 22.7 306 16 27.4 301 17 24.5292 18 13.8 273 19 11.6 2266. Malonate Salt:

In embodiment 6, the SALT OF THE INVENTION is the malonate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane,e.g. the mono-malonate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form. The mono-malonate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form may be produced from acetonitrile when one equivalentmalonic acid is used.

It shows good solubility in aqueous media (>30 mg/ml).

It is slightly hygroscopic: when tested, LOD of a sample was 0% andmoisture gain was 1.3% at 85% RH.

Its melting point was determined by heating at 2° C./minute to be 140°C. (onset) with subsequent decomposition.

The XRPD pattern of a sample prepared according to this method (see alsoExample 6) is shown in FIG. 6. Measurements were performed at atemperature of about 22° C. and an x-ray wavelength, λ, of 1.5418 Å(CuKα λ=1.5418 Å).

Summary of XRPD Pattern:

2 theta No. (deg°) Intensity 1 5 78.1 2 24.3 75 3 16.8 63.2 4 18.1 55.85 13 53.2 6 19.8 53 7 17.1 52.3 8 15.6 51.9 9 20.2 50.7 10 18.7 33 1115.1 31.3 12 29.1 28.5 13 12.2 23.6 14 28.8 23.5 15 27.5 21.4 16 27 20.117 20.9 18 18 30.1 17.9 19 32.2 14.3 20 31 13.4 21 14.3 13.3 22 10.211.8 23 21.4 11.3 24 34 10.6 25 33.5 10.5 26 25.9 9.4 27 25.2 9.1 2834.5 8.7 29 35.8 8.3 30 35.2 7.2

In one embodiment, the mono-malonate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form is characterized by an XRPD pattern with at least four,more preferably five, most preferably all of the following peaks at anangle of refraction 2 theta (2θ) of 5.0, 13.0, 16.8, 18.1, 19.8 and24.3, ±0.2, respectively.

In one embodiment, the mono-malonate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form is characterized by an XRPD pattern substantially thesame as the XRPD pattern shown in FIG. 6.

Preparation Methods for Crystalline Forms

Crystalline forms may be prepared by a variety of methods, including forexample, crystallization or recrystallization from a suitable solvent,sublimation, growth from a melt, solid state transformation from anotherphase, crystallization from a supercritical fluid, and jet spraying.Techniques for crystallization or recrystallization of crystalline formsfrom a solvent mixture include, for example, evaporation of the solvent,decreasing the temperature of the solvent mixture, crystal seeding asupersaturated solvent mixture of the molecule and/or salt, freezedrying the solvent mixture, and addition of antisolvents(countersolvents) to the solvent mixture. High throughputcrystallization techniques may be employed to prepare crystalline formsincluding polymorphs.

Crystals of drugs, including polymorphs, methods of preparation, andcharacterization of drug crystals are discussed in Solid-State Chemistryof Drugs, S. R. Byrn, R. R. Pfeiffer, and J. G. Stowell, 2^(nd) Edition,SSCI, West Lafayette, Ind. (1999).

For crystallization techniques that employ solvent, the choice ofsolvent or solvents is typically dependent upon one or more factors,such as solubility of the compound, crystallization technique, and vaporpressure of the solvent. Combinations of solvents may be employed, forexample, the compound may be solubilized into a first solvent to afforda solution, followed by the addition of an antisolvent to decrease thesolubility of the compound in the solution and to afford the formationof crystals. An antisolvent is a solvent in which the compound has lowsolubility.

In one method to prepare crystals, a compound is suspended and/orstirred in a suitable solvent to afford a slurry, which may be heated topromote dissolution. The term “slurry”, as used herein, means asaturated solution of the compound, which may also contain an additionalamount of the compound to afford a heterogeneous mixture of the compoundand a solvent at a given temperature.

Seed crystals may be added to any crystallization mixture to promotecrystallization (see “Programmed Cooling of Batch Crystallizers,” J. W.Mullin and J. Nyvlt, Chemical Engineering Science, 1971, 26, 369-377).In general, seed crystals of small size are used. Seed crystals of smallsize may be generated by sieving, milling, or micronizing of largecrystals, or by micro-crystallization of solutions. Care should be takenthat milling or micronizing of crystals does not result in any change incrystallinity form the desired crystal form (i.e., change to amorphousor to another polymorph).

A cooled crystallization mixture may be filtered under vacuum, and theisolated solids may be washed with a suitable solvent, such as coldrecrystallization solvent, and dried under a nitrogen purge to affordthe desired crystalline form. The isolated solids may be analyzed by asuitable spectroscopic or analytical technique, such as solid statenuclear magnetic resonance, differential scanning calorimetry, x-raypowder diffraction, or the like, to assure formation of the preferredcrystalline form of the product. The resulting crystalline form istypically produced in an amount of greater than about 70 weight %isolated yield, preferably greater than 90 weight % isolated yield,based on the weight of the compound originally employed in thecrystallization procedure. The product may be delumped by sieving orforced sieving, if necessary.

Crystalline forms may be prepared directly from the reaction medium ofthe final process for preparing(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane ora SALT OF THE INVENTION. This may be achieved, for example, by employingin the final process step a solvent or a mixture of solvents from whichthe SALT OF THE INVENTION may be crystallized. Alternatively,crystalline forms may be obtained by distillation or solvent additiontechniques. Suitable solvents for this purpose include, for example,nonpolar solvents and polar solvents, including protic polar solventssuch as alcohols, and aprotic polar solvents such as ketones.

The presence of more than one polymorph in a sample may be determined bytechniques such as powder x-ray diffraction (PXRD) or solid statenuclear magnetic resonance spectroscopy. For example, the presence ofextra peaks in the comparison of an experimentally measured PXRD patternwith a simulated PXRD pattern may indicate more than one polymorph inthe sample. The simulated PXRD may be calculated from single crystalx-ray data; see Smith, D. K., “A FORTRAN Program for Calculating X-RayPowder Diffraction Patterns,” Lawrence Radiation Laboratory, Livermore,Calif., UCRL-7196 (April 1963).

In many cooled and/or seeded crystallizations of the mono-fumarate saltof (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanefine particles are obtained. Fine particles typically have the drawbackof bad filtration properties and poor flowability, which is especiallydisadvantageous for the widely used dry-granulation using rollercompaction. It was found that, depending on crystallization techniques,a mean particle size of the crystals of above 15 μm can be obtained. Aslaid out above, such mean particle sizes are especially suitable forformulation work.

The term “mean particle size” (X₅₀) refers to a crystal sizedistribution wherein 50% of crystals related to the total volume ofparticles have a smaller diameter of an equivalent sphere than the valuegiven.

The term “X₉₀” refers to a crystal size distribution wherein 90% ofcrystals related to the total volume of particles have a smallerdiameter of an equivalent sphere than the value given.

The term “X₁₀” refers to a crystal size distribution wherein 10% ofcrystals related to the total volume of particles have a smallerdiameter of an equivalent sphere than the value given.

Consequently, one embodiment of the invention is a method of preparing amono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form comprising the steps of

(a) preparing a solution of a mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane ina solvent mixture of a primary alcohol, a secondary alcohol and water,wherein the primary alcohol:secondary alcohol volume ratio is from 9:1to 1:1, and wherein the alcohols:water volume ratio is from 9:1 to 19:1;(b) heating the solution of step (a) to elevated temperature;(c) adding the solution of step (b) gradually to an ether antisolvent ata temperature ranging from ambient temperature to 55° C. until asolution from step (b): ether antisolvent volume ratio from 1:1 to 1:5is reached; wherein after an amount of the solution of step (b) from 10%to 40% of the total amount is added, the resulting solution is seededwith seed crystals of a mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form, wherein the seed crystals are suspended in a secondaryalcohol;(d) cooling the seeded solution of step (c) gradually to a temperaturebelow ambient; and(e) isolate the solids by filtration to obtain the mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form.

Examples of primary alcohols are methanol or ethanol. An example of asecondary alcohol is isopropanol. An example of an ether antisolvent istertiary-butylmethylether.

Typically, the mean particle size of the seed crystals is from 1 μm to10 μm. Typically the seed crystals are added in an amount of from 0.08%to 2% of the amount of the salt in step (a).

One embodiment of the invention is a method of preparing a mono-fumaratesalt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form comprising the steps of

(a) preparing a solution of a mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane ina mixture of ethanol, isopropanol and water, wherein theethanol:isopropanol volume ratio is about 75:15, and wherein thealcohols:water volume ratio is about 90:10;(b) heating the solution of step (a) to a temperature of about 50° C.;(c) adding the solution of step (b) gradually totertiary-butylmethylether at a temperature of about 50° C. until a asolution from step (b): tertiary-butylmethylether volume ratio of about75:25 is reached; wherein after an amount of the solution of step (b) ofabout 25% of the total amount is added, the resulting solution is seededwith seed crystals of a mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form, wherein the mean particle size of the seed crystals isabout 10 μm, wherein the seed crystals are added in an amount of about0.08% of the amount of the salt in step (a), and wherein the seedcrystals are suspended in isopropanol;(d) cooling the seeded solution of step (c) gradually to a temperatureranging of about 0° C.; and(e) isolate the solids by filtration to obtain the mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form.

One further embodiment of the invention is mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form, wherein the mean particle size of the crystals is atleast 15 μm.

One further embodiment of the invention is mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form, wherein the mean particle size of the crystals is atleast 20 μm.

One further embodiment of the invention is mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form, wherein the mean particle size of the crystals is atleast 25 μm.

One further embodiment of the invention is mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form, wherein the mean particle size of the crystals is from20 μm to 35 μm.

One further embodiment of the invention is mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form, wherein the mean particle size of the crystals is from20 μm to 35 μm; the X₁₀ is from 3 μm to 10 μm; and the X₉₀ is from 70 μmto 90 μm.

One further embodiment of the invention is mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form, wherein the mean particle size of the crystals is from25 μm to 30 μm.

Analysis of Solid Forms

The solid form of a SALT OF THE INVENTION may be characterized usingvarious techniques, the operation of which are well known to those ofordinary skill in the art.

The forms may be characterized and distinguished using single crystalx-ray diffraction, which is based on unit cell measurements of a singlecrystal of the form at a fixed analytical temperature. A detaileddescription of unit cells is provided in Stout & Jensen, X-Ray StructureDetermination: A Practical Guide, Macmillan Co., New York (1968),Chapter 3. Alternatively, the unique arrangement of atoms in spatialrelation within the crystalline lattice may be characterized accordingto the observed fractional atomic coordinates. Another means ofcharacterizing the crystalline structure is by powder x-ray diffractionanalysis in which the diffraction profile is compared to a simulatedprofile representing pure powder material, both run at the sameanalytical temperature, and measurements for the subject formcharacterized as a series of 2θ values (usually four or more).

Other means of characterizing the form may be used, such as solid statenuclear magnetic resonance (NMR), differential scanning calorimetry,thermography and gross examination of the crystalline or amorphousmorphology. These parameters may also be used in combination tocharacterize the subject form.

Mean particle sizes, X₉₀ and X₁₀ are typically measured by Fraunhoferlight diffraction.

Utility

SALTS OF THE INVENTION exhibit valuable pharmacological propertiesadministered to animals/humans, and are therefore useful aspharmaceuticals. SALTS OF THE INVENTION are selective α7-nAChR partialagonists.

Due to their pharmacological profiles, SALTS OF THE INVENTION areanticipated to be useful for the treatment of diseases or conditions asdiverse as CNS related diseases, PNS related diseases, diseases relatedto inflammation, pain and withdrawal symptoms caused by an abuse ofchemical substances.

Diseases or disorders related to the CNS include general anxietydisorders, cognitive disorders, learning and memory deficits anddysfunctions, Alzheimer's disease (AD), prodromal AD, mild cognitiveimpairment in the elderly (MCI), amnestic MCI, age associated memoryimpairment, attention deficit and hyperactivity disorder (ADHD),Parkinson's disease, L-dopa induced dyskinesias associated withParkinson's disease, Huntington's disease, ALS, prionicneurodegenerative disorders such as Creutzfeld-Jacob disease and kurudisease, Gilles de la Tourette's syndrome, psychosis, depression anddepressive disorders, mania, manic depression, schizophrenia, thecognitive deficits in schizophrenia, obsessive compulsive disorders,panic disorders, eating disorders, nociception, AIDS-dementia, seniledementia, mild cognitive dysfunctions related to age, autism, dyslexia,tardive dyskinesia, epilepsy, and convulsive disorders, post-traumaticstress disorders, transient anoxia, pseudodementia, pre-menstrualsyndrome, late luteal phase syndrome and jet lag.

Furthermore, SALTS OF THE INVENTION may be useful for the treatment ofendocrine disorders, such as thyrotoxicosis, pheochromocytoma,hypertension and arrhythmias as well as angina pectoris, hyperkinesia,premature ejaculation and erectile difficulty.

Still further, SALTS OF THE INVENTION may be useful in the treatment ofinflammatory disorders (Wang et al., Nature 2003, 421, 384; de Jonge etal., Nature Immunology 2005, 6, 844; Saeed et al., JEM 2005, 7, 1113),disorders or conditions including inflammatory skin disorders,rheumatoid arthritis, post-operative ileus, Crohn's disease,inflammatory bowel disease, ulcerative colitis, sepsis, fibromyalgia,pancreatitis and diarrhoea.

SALTS OF THE INVENTION may further be useful for the treatment ofwithdrawal symptoms caused by termination of the use of addictivesubstances, like heroin, cocaine, tobacco, nicotine, opioids,benzodiazepines and alcohol.

Furthermore, SALTS OF THE INVENTION may be useful for the treatment ofpain, e.g. caused by migraine, postoperative pain, phantom limb pain orpain associated with cancer. The pain may comprise inflammatory orneuropathic pain, central pain, chronic headache, pain related todiabetic neuropathy, to post therapeutic neuralgia or to peripheralnerve injury.

Furthermore, degenerative ocular disorders which may be treated includeocular diseases which may directly or indirectly involve thedegeneration of retinal cells, including ischemic retinopathies ingeneral, anterior ischemic optic neuropathy, all forms of opticneuritis, age-related macular degeneration (AMD), in its dry forms (dryAMD) and wet forms (wet AMD), diabetic retinopathy, cystoid macularedema (CME), retinal detachment, retinitis pigmentosa, Stargardt'sdisease, Best's vitelliform retinal degeneration, Leber's congenitalamaurosis and other hereditary retinal degenerations, pathologic myopia,retinopathy of prematurity, and Leber's hereditary optic neuropathy.

SALTS OF THE INVENTION can be combined with at least one compoundselected from the group consisting of (a) conventional antipsychoticsand (b) atypical antipsychotics, in which the antipsychotic is presentin free form or in the form of a pharmaceutically acceptable salt; forsimultaneous, separate or sequential use to treat psychiatric disorders.The term “psychiatric disorders” as used herein includes, but is notlimited to schizophrenia, anxiety disorders, depression and bipolardisorders. Preferably, the psychiatric disorder is schizophrenia, morepreferably schizophrenia which is refractory to monotherapy employingone of the combination partners alone.

The term “conventional antipsychotics” as used herein includes, but isnot limited to haloperidol, fluphenazine, thiotixene and flupentixol.

The term “atypical antipsychotics” as used herein includes, but is notlimited to clozaril, risperidone, olanzapine, quetiapine, ziprasidoneand aripiprazol.

SALTS OF THE INVENTION are useful in the treatment of the abovediseases/conditions.

Consequently, the invention also relates to a SALT OF THE INVENTION(e.g. the mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form) for use as a medicament.

In another embodiment, the invention also relates to a SALT OF THEINVENTION (e.g. the mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form) for use in the prevention, treatment and/or delay ofprogression of a disease or condition, in which α7-nAChR activationplays a role or is implicated.

In another embodiment, the invention also relates to a SALT OF THEINVENTION (e.g. the mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form) for use in the prevention, treatment and/or delay ofprogression of a psychiatric or neurodegenerative disorder.

In another embodiment, the invention also relates to the use of a SALTOF THE INVENTION (e.g. the mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form) for the manufacture of a medicament for theprevention, treatment and/or delay of progression of a disease orcondition, in which α7-nAChR activation plays a role or is implicated.

In another embodiment, the invention also relates to the use of a SALTOF THE INVENTION (e.g. the mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form) for the manufacture of a medicament for theprevention, treatment and/or delay of progression of a psychiatric orneurodegenerative disorder.

In another embodiment, the invention also relates to a method for theprevention, treatment and I or delay of progression of a disease orcondition, in which α7-nAChR activation plays a role or is implicated,in a subject in need of such treatment, which comprises administering tosuch subject a therapeutically effective amount of a SALT OF THEINVENTION (e.g. the mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form).

In another embodiment, the invention relates to a method for theprevention, treatment and/or delay of progression of a psychiatric orneurodegenerative disorder in a subject in need of such treatment, whichcomprises administering to such subject a therapeutically effectiveamount of a SALT OF THE INVENTION (e.g. the mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form).

In another embodiment, the invention relates to a method for theprevention, treatment and/or delay of progression of a disease orcondition, in which α7-nAChR activation plays a role or is implicated,in a subject in need thereof, which comprises (i) diagnosing saiddisease or condition in said subject and (ii) administering to saidsubject a therapeutically effective amount of a SALT OF THE INVENTION(e.g. the mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form).

In another embodiment, the invention relates to a method for theprevention, treatment and/or delay of progression of a psychiatric orneurodegenerative disorder, in a subject in need thereof, whichcomprises (i) diagnosing said disorder in said subject and (ii)administering to said subject a therapeutically effective amount of aSALT OF THE INVENTION (e.g. the mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form).

Treatment may comprise a reduction in the characteristics associatedwith the disease, condition or disorder, including, although not limitedto, e.g. for schizophrenia: reduction in positive symptoms, negativesymptoms, mood symptoms and/or cognitive symptoms and/or reduction inimpulsive or violent behaviour.

In the case of prophylactic treatment, the SALT OF THE INVENTION may beused to delay or prevent the onset of the Instant Movement Disorder.

The term “subject” as used herein refers preferably to a human being,especially to a patient being diagnosed with the disease, condition ordisorder.

The term “therapeutically effective amount” as used herein typicallyrefers to a drug amount which, when administered to a subject, issufficient to provide a therapeutic benefit, e.g. is sufficient fortreating, preventing or delaying the progression of the disease,condition or disorder (e.g. the amount provides an amelioration ofsymptoms, e.g. it leads to a reduction of positive symptoms inschizophrenic patients).

For the above-mentioned indications (the diseases, conditions and/ordisorders) the appropriate dosage will vary depending upon, for example,the host, the mode of administration and the nature and severity of thecondition being treated. However, in general, satisfactory results inanimals are indicated to be obtained at a daily dosage of from about0.01 to about 100 mg/kg body weight, preferably from about 0.1 to about10 mg/kg body weight, e.g. 1 mg/kg. In larger mammals, for examplehumans, an indicated daily dosage is in the range from about 0.1 toabout 1000 mg, preferably from about 1 to about 400 mg, most preferablyfrom about 3 to about 100 mg of a SALT OF THE INVENTION convenientlyadministered, for example, in divided doses up to four times a day.

Amorphous forms/crystalline forms of SALTS OF THE INVENTION are usefulas intermediates for preparing crystalline forms/other crystalline formsof SALTS OF THE INVENTION that are useful in the treatment of the abovediseases/conditions.

Formulations Comprising Salts of the Invention

SALTS OF THE INVENTION may be used alone or in combination, orformulated with one or more excipients and/or other activepharmaceutical ingredients to provide formulations suitable for thetreatment of the above diseases/conditions.

The invention therefore also relates to a pharmaceutical compositioncomprising a SALT OF THE INVENTION as active ingredient and at least onepharmaceutically acceptable carrier.

A pharmaceutical composition according to the invention is, preferably,suitable for enteral administration, such as oral or rectaladministration; or parenteral administration, such as intramuscular,intravenous, nasal or transdermal administration, to a warm-bloodedanimal (human beings and animals) that comprises a therapeuticallyeffective amount of the active ingredients and one or more suitablepharmaceutically acceptable carriers.

Preferred are compositions for oral or transdermal administration.

A composition for enteral or parenteral administration is, for example,a unit dosage form, such as a coated tablet, a tablet, a capsule, asuppository or an ampoule.

The unit content of active ingredient(s) in an individual dose need notin itself constitute a therapeutically effective amount, since such anamount can be reached by the administration of a plurality of dosageunits.

A composition according to the invention may contain from e.g. 0.1 to100% active ingredient(s) by weight, e.g. from 1 to 10% by weight, e.g.from 11 to 25% by weight, or from 20 to 60% by weight.

If not indicated otherwise, a pharmaceutical composition according tothe invention is prepared in a manner known per se, e.g. by means ofconventional mixing, granulating, sugar-coating, dissolving orlyophilizing processes. In preparing e.g. a composition for an oraldosage form, any of the usual pharmaceutical carriers may be employed,for example water, glycols, oils, alcohols, fillers, such as starches,sugars, or microcrystalline cellulose, granulating agents, lubricants,binders, disintegrants, gliding agents and the like. Because of theirease of administration, tablets and capsules represent the mostadvantageous oral dosage unit forms, in which case solid pharmaceuticalcarriers are obviously employed.

Examples of fillers are a starch, e.g. maize starch or corn starch; asugar, e.g. sprayed lactose; or a cellulose, e.g. microcrystallinecellulose (e.g. Avicel®), methylcellulose, hydroxypropylcellulose,hydroxypropylmethylcellulose. Fillers typically are present in an amountof from e.g. 1 to 70% by weight.

Examples of disintegrants are sodium starch glycolate, e.g. sodiumstarch glycolate type A; sodium or calcium carboxymethyl cellulose(sodium or calcium carmellose); crosslinked sodium carboxymethylcellulose (sodium croscarmellose); starch; hydroxypropyl starch; lactosemonohydrate and corn starch; chitosan; povidone; or crosslinked povidone(crospovidone). Disintegrants typically are present in an amount of frome.g. 0.5 to 15% by weight, especially 1.5 to 5% by weight.

Examples of lubricants are stearic acid, magnesium stearate, calciumstearate, zinc stearate, glyceryl palmitostearate, sodium stearylfumarate, sodium lauryl sulfate, glyceryl behenates, hydrogenatedvegetable oils, wax cetyl esters or talc. Lubricants typically arepresent in an amount of from typically 0.5 to 10% by weight, especially1.5 to 3% by weight.

Examples of gliding agents are colloidal silicon dioxide, talc, tribasiccalcium phosphate, powdered cellulose, hydrophobic colloidal silica,magnesium oxide, magnesium silicate, magnesium trisilicate. Glidingagents typically are present in an amount of from e.g. 0.01 to 5% byweight, especially 0.1 to 1% by weight.

Tablets may optionally be coated, for instance with talc or apolysaccharide (e.g. cellulose) or hydroxypropylmethylcellulose coating.As an example, the coating formulation could be one of the formulationsdescribed in the table below or a mixture of them.

Colour White Yellow Red Black (w/w)% (w/w)% (w/w)% (w/w)% Hydroxypropylmethylcellulose 3 cps 60-80 60-80 60-80 60-80 Polyethylene glycol 4000 5-10  5-10  5-10  5-10 Talc  5-10  5-10  5-10  5-10 Titanium dioxide 1-20 — — — Iron oxide yellow —  1-20 — — Iron oxide red — —  1-20 —Iron oxide black — — —  1-20

The invention also relates to a pharmaceutical composition comprisingmono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane asactive ingredient and at least one pharmaceutically acceptable carrier,wherein the composition is in the form of a tablet.

The invention also relates to a pharmaceutical composition comprisingmono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane asactive ingredient and at least one pharmaceutically acceptable carrier,wherein the composition is in the form of a capsule.

Tablets/capsules need to be in a certain size range: they should be nottoo big to avoid discomfort/problems when swallowed; but also not toosmall as they need to be reliably packaged and they should be easy tohandle e.g. during multiple patient dosing in hospitals and/orindividual dosing by elderly patients themselves.

It is furthermore important that they have good physicochemical andstorage properties. The tablets/capsules should be easy to manufactureand should show a high level of uniformity in the distribution of theactive ingredient throughout the composition.

It is particularly important that the active ingredient remainschemically stable over a potential long shelf time. When assessingstorage stability, relative amounts of individual degradation productscompared to the total amount of active ingredient are taken intoconsideration. Individual degradation products should all be present inlow relative amounts to ensure that no single product can reach anon-acceptable level, e.g. when the active ingredient is administered inhigh doses.

It has been found that mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane isvery stable in tablets where only certain lubricants are used.

The invention also relates to a pharmaceutical composition in the formof a tablet comprising

(a) mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane asactive ingredient;

(b) a filler;

(c) a disintegrant;

(d) a lubricant; and

(e) a gliding agent;

wherein the only lubricant present is a lubricant selected from sodiumstearyl fumarate, sodium lauryl sulfate, glyceryl behenates,hydrogenated vegetable oils, wax cetyl esters and talc.

The invention also relates to a pharmaceutical composition in the formof a tablet comprising

(a) up to 10% by weight mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane asactive ingredient (e.g. from 0.1 to 3% by weight, e.g. about 0.7% byweight);

(b) a filler comprising maize starch (e.g. from 1 to 20% by weight, e.g.about 13% by weight); microcrystalline cellulose (e.g. from 15 to 35% byweight, e.g. about 25% by weight); and sprayed lactose (e.g. from 40 to75% by weight, e.g. about 68% by weight);(c) a disintegrant comprising sodium carboxymethylcellulose XL (e.g.from 0.5 to 5% y weight, e.g. about 2% by weight);(d) a lubricant (e.g. from 0.5 to 3% by weight, e.g. about 1.5% byweight); and(e) a gliding agent comprising Aerosil (e.g. from 0.1 to 1% by weight,e.g. about 0.5% by weight);wherein the only lubricant present is sodium stearyl fumarate.

It has been found that tablets comprising mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane inlow weight percentages which are manufactured as bilayer tablets arevery stable. Such bilayer tablets comprise an active ingredient layerand an auxiliary layer being devoid of the mono-fumarate.

The invention also relates to a pharmaceutical composition in the formof a tablet comprising from 1 to 10% by weight mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane asactive ingredient and at least one pharmaceutically acceptable carrier;

wherein the composition comprises an active ingredient layer comprisingthe mono-fumarate and an auxiliary layer being devoid of themono-fumarate;

wherein the weight ratio of the active ingredient layer to the auxiliarylayer is from 10:90 to 90:10 (e.g. form 20:80 to 50 to 50; e.g. from20:80 to 40:60; e.g. about 22.5 to 77.5).

The invention also relates to a pharmaceutical composition in the formof a tablet comprising from 1 to 10% by weight mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane asactive ingredient (e.g. from 1 to 5% by weight, e.g. from 2 to 4% byweight);

wherein the composition comprises an active ingredient layer comprisingthe mono-fumarate and an auxiliary layer being devoid of themono-fumarate;

wherein the weight ratio of the active ingredient layer to the auxiliarylayer is from 10:90 to 90:10 (e.g. form 20:80 to 50 to 50; e.g. from20:80 to 40:60; e.g. about 22.5 to 77.5); wherein the active ingredientlayer comprises

(1a) from 11 to 25% by weight of the active ingredient layermono-fumarate (e.g. from 11 to 20% by weight of the active ingredientlayer, e.g. about 15.5% by weight of the active ingredient layer);

(1b) a filler;

(1c) a disintegrant;

(1d) a lubricant; and

(1e) a gliding agent; and

wherein the auxiliary layer comprises

(2a) a filler;

(2b) a disintegrant;

(2c) a lubricant; and

(2d) a gliding agent.

The invention also relates to a pharmaceutical composition in the formof a tablet comprising from 1 to 10% by weight mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane asactive ingredient (e.g. from 1 to 5% by weight, e.g. from 2 to 4% byweight);

wherein the composition comprises an active ingredient layer comprisingthe mono-fumarate and an auxiliary layer being devoid of themono-fumarate;

wherein the weight ratio of the active ingredient layer to the auxiliarylayer is from 10:90 to 90:10 (e.g. form 20:80 to 50 to 50; e.g. from20:80 to 40:60; e.g. about 22.5 to 77.5); wherein the active ingredientlayer comprises

(1a) from 11 to 25% by weight of the active ingredient layermono-fumarate (e.g. from 11 to 20% by weight of the active ingredientlayer, e.g. about 15.5% by weight of the active ingredient layer);

(1b) a filler comprising microcrystalline cellulose (e.g. from 15 to 35%by weight of the active ingredient layer, e.g. about 25% by weight); andsprayed lactose (e.g. from 40 to 70% by weight of the active ingredientlayer, e.g. about 53% by weight);

(1c) a disintegrant comprising sodium carboxymethylcellulose XL (e.g.from 1 to 5% by weight of the active ingredient layer, e.g. about 3% byweight);

(1d) a lubricant comprising sodium stearyl fumarate (e.g. from 1 to 5%by weight of the active ingredient layer, e.g. about 3% by weight); and

(1e) a gliding agent comprising Aerosil (e.g. from 0.1 to 1% by weightof the active ingredient layer, e.g. about 0.5% by weight); and

wherein the auxiliary layer comprises

(2a) a filler comprising microcrystalline cellulose (e.g. from 10 to 35%by weight of the auxiliary layer, e.g. about 26% by weight); and sprayedlactose (e.g. from 50 to 75% by weight of the auxiliary layer, e.g.about 69% by weight);

(2b) a disintegrant comprising sodium carboxymethylcellulose XL (e.g.from 1 to 3% by weight of the auxiliary layer, e.g. about 1.9% byweight);

(2c) a lubricant comprising sodium stearyl fumarate (e.g. from 1 to 5%by weight of the auxiliary layer, e.g. about 3% by weight); and

(2d) a gliding agent comprising Aerosil (e.g. from 0.1 to 1% by weightof the auxiliary layer, e.g. about 0.5% by weight).

II. Methods to Make Salts of Aza-Bicyclic Di-Aryl Ethers or theirIntermediates

The present invention relates also to novel processes for the productionof (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanein free form or in salt form and its direct precursor,5-chloro-2-(4-methylphenyl)-pyridine.

The compound 5-chloro-2-(4-methylphenyl)-pyridine of the formula II

is a valuable intermediate in the production of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane ofthe formula I

Both compounds are described in WO2004/022556A1.(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanehas good pharmacological properties and can be used as an α7-nAChRagonist useful in therapy for disorders which respond to α7-nAChRmodulation, e.g. neurodegenerative (e.g. Alzheimers Disease) and/orpsychiatric (e.g. schizophrenia) disorders. Depending onindication/patient population size, pharmaceuticals may be produced inlarge quantities. For example, the blood pressure medicament valsartan(being sold as Diovan™) is produced in quantities of several hundredmetric tons per annum.

WO2004/022556A1 discloses a process for the production of5-chloro-2-(4-methylphenyl)-pyridine wherein 2-bromo-5-chloropyridine isreacted with 4-methyl-phenylboronic acid in the presence of the baseNa₂CO₃ and the palladium catalyst tetrakis(triphenylphosphine)palladium(catalyst load being 4.6 mol %) at about pH9.8.

This process has several draw-backs regarding cost-effectiveness forlarge scale production: a) 2-bromo-5-chloro-pyridine is commercially notreadily available and is costly as a starting material; b) the usedpalladium (0) catalyst tends to gradually degrade on storage andrequires strict handling precautions; furthermore because of itssensitivity it is added usually in comparably high loads of about 5 mol% to such reactions; c) the applied high catalyst load results in anunacceptably high levels of residual palladium in the crude reactionproduct, because this compound itself is a good palladium ligand, andadditional costly purification operations are required (e.g.chromatography and/or treatment with palladium complexing agents); d) anuneconomically high dilution of 0.40 (w/w) % (mass percentage) isapplied in order to subdue competing side reactions at the requiredelevated temperatures of 75-100° C.; and e) the reaction conditions areassociated with slow starting material conversion rates which may resultin incomplete conversion even after 24 hours; thus parallel progressionof catalyst deactivation/competing side reactions may further contributeto high production costs due to lost yield and additional purificationefforts.

WO2004/022556A1 also discloses a process for the production of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanewherein 5-chloro-2-(4-methylphenyl)-pyridine is reacted with(R)-1-aza-bicyclo[2.2.2]octan-3-ol by heating in the presence of thebase sodium hydride using dimethylformamide as solvent.

This process is not well-suited for industrial scale up because heatingof sodium hydride in the presence of solvents like dimethylformamide isknown to be unsafe and may lead to hazardous run-away conditions.

The aim of the invention is therefore to provide novel processes for theproduction of the di-aryls 5-chloro-2-(4-methylphenyl)-pyridine and(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanewhich make it possible to prepare said compounds in high yields and goodquality in an economically advantageous and easily handled way.

The processes according to the present invention are summarized inScheme 1.

Namely, a compound of formula (III) is converted into a compound offormula (I), or a salt thereof, comprising

a) any one of the methods in Section A to convert the compound offormula (III) into a compound of formula (II) or a salt thereof; and

b) any one of the methods in Section B to convert the compound offormula (II) or the salt thereof into the compound of formula (I), or asalt thereof.

Sections A and B as such are also preferred embodiments of the presentinvention.

The invention specially relates to the processes described in eachsection. The invention likewise relates, independently, to every singlestep described in a process sequence with the corresponding section.Therefore, each and every single step of any process, consisting of asequence of steps, described herein is itself a preferred embodiment ofthe present invention.

It is noted that explanations made in one section are also applicablefor other sections, unless otherwise stated.

Section A:

In Section A, the present invention relates to a process for theproduction of a compound of formula II or a salt thereof

comprisinga) reacting a compound of formula III

with a compound of formula IV

and/orwith a compound of formula IVA

wherein M₁ is alkali and n is 1 or M₁ is earth alkali and n is 2;in the presence of a palladium catalyst; a base selected from acarbonate base, a phosphate base, a hydroxide base and an alcoholatebase; water and an inert solvent;to form the compound of formula II; andb) optionally converting the compound of formula II to a salt thereof.Reaction Step a)

In one embodiment of the process of Section A, compounds of formula IIin free base form are produced.

The compound of formula III is readily commercially available. Thisstarting compound is distinguished from the corresponding prior artstarting compound (i.e. 2-bromo-5-chloropyridine) by being especiallyreadily accessible and economical. It is known, however, that, under theconditions of palladium-catalysed Suzuki-coupling, this class ofstarting compounds, the 2-chloro-pyridines, are more difficult to couplewith high yield/good purity, because of the lower reactivity of thechlorine leaving group, compared to bromo-analogs. As the inventionmakes those starting compounds accessible to the palladium-catalysedSuzuki-coupling in high yield/good purity, the process of Section A isespecially interesting from an economic point of view. Furthermore, lowpalladium catalyst loads of <1 mol % may be used.

The compound of formula IV is readily commercially available. In oneembodiment of the process of Section A, a compound of formula IV isused.

The term “alkali” in compounds of formula IVA refers typically to sodiumor potassium; the term “earth alkali” refers typically to magnesium orcalcium. Compounds of formula IVA are accessible according to knownmethods (e.g. Organic letters (8), 2006, 4071-4074 and cited referencestherein). In one embodiment of the process of Section A, a compound offormula IVA is used.

In the process of Section A, compounds of formula III can be usedtypically in mass percentages of between 0.5 (w/w) % and 10 (w/w) %.More preferably, compounds of formula III are used in mass percentagesbetween 2.5 (w/w) % and 8 (w/w) %. Even more preferably, compounds offormula III are used in mass percentages between 4.5 (w/w) % and 6.5(w/w) %, e.g. about 5.1 (w/w) %. The possibility of using high masspercentages/concentrations of compounds of formula III is an importantadvantage of the process according to the invention as with highconcentrations of starting materials less solvent is needed, which makesthe process according to the invention especially suitable forindustrial-scale production.

Mass percentages (w/w) % are calculated by division of the mass of thecompound in question with the mass of the total reaction mixture (priorto workup) and multiplied by 100.

In the process of Section A, compounds of formula IV or compounds offormula IVA are typically used in equimolar amounts or in excessrelative to compounds of formula III, preferably in an up to 2-foldexcess, especially in an up to 1.5-fold excess, more especially in an upto about 1.1-fold excess. In one embodiment, compounds of formula IV areused in an about 1.1-fold excess.

In the process of Section A, the palladium catalyst typically is (butnot limited to)

(a) a palladium (0)- or palladium (II)-triarylphosphine or palladium(II)-bisdiphenyl complex optionally in the presence of additionalamounts of a triarylphosphine ligand, or

(b) a palladium (II) salt in the presence of a mono- or bisdentatearylphosphine ligand, or

(c) metallic palladium, optionally deposited on a support, in thepresence of triarylphosphine.

Such catalysts are well known; see, e.g. Angewandte Chemie (105), 1993,1589ff; or Tetrahedron (58), 2002, 9633ff.

Of the palladium complexes having palladium in the oxidation state 0,tetrakis(triphenyl-phosphine)palladium andtetrakis[tri(o-tolyl)phosphine)palladium are particularly suitable.

Of the palladium complexes having palladium in the oxidation state +2,di-(triphenyl-phosphine)palladium(II) acetate (Pd(O₂CCH₃)₂([C₆H₅]₃P)₂),di-(triphenyl)phosphine)-palladium(II) chloride (PdCl₂([C₆H₅]₃P)₂), ande.g. 1,1′-bis-(diphenylphosphine)ferrocene palladium (II) chloride(PdCl₂(dppf)) are particularly suitable.

In one embodiment of the invention, the palladium catalyst isdi-(triphenylphosphine)-palladium(II) chloride.

It is understood that the reactivity of the arylhalogen component in thecatalytic cycle of the cross coupling reaction can be fine-tuned withPd-catalysts containing special, less readily available ligands. Thepreferred scope of the invention is on commercially readily availableand air-stable Pd(II) catalysts.

A palladium(II) salt employed in the presence of a triarylphosphineligand, for example a triphenylphosphine or tri(o-tolyl)phosphineligand, is suitably palladium(II) acetate or palladium dichloride.

Typically, from 2 to 6 equivalents of the triarylphosphine ligand iscomplexed with one equivalent of the palladium salt or additionally usedwith the palladium-triarylphosphine complex.

Metallic palladium is preferably used as a powder or on a support, forexample, as palladium on activated carbon, palladium on aluminium oxide,palladium on barium carbonate, palladium on barium sulphate, palladiumon calcium carbonate, palladium on aluminium silicates such asmontmorillonite and palladium on silic, in each case having a palladiumcontent of 0.5 to 12% by weight. Such supported catalysts may additionalcontain further doping substances, for example, lead.

When using supported metallic palladium catalysts, the simultaneous useof a complexed ligand, of the type discussed above, is beneficial,particularly the use of palladium on activated carbon in the presence oftriphenylphosphine, tri(o-tolyl)phosphine or other triarylphosphine ascomplexed ligand, the aryl groups being suitably substituted with 1 to 3sulphonate groups. Suitably, 2 to 3 equivalents of these ligands areused for each equivalent of palladium metal.

In the process of Section A, the palladium catalyst is typicallyemployed in a ratio of from 0.01 to 10 mol %, preferably from 0.05 to 3mol % and especially from 0.1 to 1 mol %, based on the amount of thecompound of formula III. In one embodiment, the palladium catalyst isemployed in a ratio of 0.6 mol %, based on the amount of the compound offormula III.

Suitable carbonate bases for the process of Section A are e.g. alkali orearth alkali carbonates, e.g. Na₂CO₃, K₂CO₃ or Cs₂CO₃; preferably K₂CO₃or Cs₂CO₃. Suitable phosphate bases for the process of Section A aree.g. K₃PO₄. Suitable hydroxide bases for the process of Section A aree.g. NaOH or KOH. Suitable alcoholate bases for the process of Section Aare e.g. e.g. sodium tert-butanolate, potassium tert-butanolate, sodiummethanolate or sodium ethanolate.

In one embodiment, preference is given to phosphate bases and specialpreference is given to K₃PO₄.

Suitable amounts of base for the process of Section A are, for example,from 1.5 to 4 equivalents, especially from 2 to 3 equivalents relativeto compounds of formula III. In one embodiment, about 3 equivalentsrelative to compounds of formula III are used. It is noted thatprocesses of Section A using compounds of formula IVA require less basethan processes using compounds of formula IV only.

The process of Section A is carried out in the presence of water.Typically a mass percentage from 35 (w/w) % to 65 (w/w) % water ispresent in the reaction mixture; preferably from 40 (w/w) % to 55 (w/w)%. In one embodiment, about 54 (w/w) % water is present.

The process of Section A is carried out typically at a pH from 10.5 to13, preferably from 11 to 12.5, more preferably at 11.5 to 12. It isunderstood that the pH-range given represents the average pH over thewhole reaction volume at any given time, whereas local pH values may betransiently different (e.g. directly at the base addition site).

Carrying out the process of Section A at the intended pH is typicallyachieved by slow addition of the base, preferably (but not limited to)as an aqueous base solution. Slow addition of the base can be doneportion-wise or continuously. It is understood that the pKa of the addedbase or the pH of the added aqueous base-solution will limit the maximalobtainable pH in the aqueous reaction mixture. During slow addition ofbase, the pH in the aqueous reaction mixture will rise gradually, e.g.when using one equivalent of 4-methyl-phenylboronic acid, the firstequivalent of base may lead to an increase from approximately pH 2.5(which may correspond to the pH of the boronic acid in the aqueousreaction mixture) to approximately pH 10 where the base consuming crosscoupling reaction starts and the pH may be further increased/maintainedby further addition of base.

The process of Section A is carried out in the presence of an inertsolvent. Said inert solvents typically have a boiling point above 60° C.Examples of said inert solvents are alcohols, e.g. isopropanol; ethers;ketones; amides; aromatic hydrocarbons; or mixtures of such solvents.Preference is given to partly water soluble solvents, such as e.g.tetrahydrofurane or isopropanol, as in the course of the reaction thesesolvents separate as a product containing organic layer from the saltrich aqueous layer and are particularly convenient for the work-upoperations. In one embodiment, the inert solvent is tetrahydrofuran;typically used in a mass percentage of about 15 (w/w) %.

The process of Section A is carried out in a temperature range fromambient temperature to elevated temperature; preferably in a temperaturerange from 30° C. to 100° C., especially in a temperature range from 35°C. to 60° C.

The reaction time of the process of Section A is generally from 0.5 to24 hours, preferably from 1 to 10 hours, especially from 2 to 5 hours.

The process of Section A may be carried out in an inert gas atmosphere.For example, nitrogen or argon is used as inert gas.

The process of Section A can be carried out at normal pressure, but isnot limited to this pressure.

In a preferred embodiment, the process of Section A comprises a work-upin which cysteine (e.g. L-cysteine or racemic cysteine) is added to thebiphasic reaction mixture to form a water soluble palladium cysteinecomplex. This complex is removed from the product containing organicphase by separation of the aqueous phase from the non-aqueous phase andthus ensures a high product quality of the compound of formula II withregard to residual palladium. The rate of complex formation isparticularly fast and therefore advantageous with regard to processcosts with preferably used partly water soluble solvents, such astetrahydrofurane or isopropanol, while with more lipophilic solvents,such as toluene or xylene, complexation rates are slower.

Consequently, one embodiment of the process of Section A is a processfor the production of a compound of formula II or a salt thereofcomprising

a1) reacting a compound of formula III with a compound of formula IVand/or a compound of formula IVA in the presence of a palladiumcatalyst; a base selected from a carbonate base, a phosphate base, ahydroxide base and an alcoholate base; water and an inert, partly watersoluble solvent;a2) adding cysteine to the biphasic reaction mixture after formation ofthe compound of formula II;a3) separating the phases;a4) isolating the compound of formula II from the non-aqueous phase; andb) optionally converting the compound of formula II to a salt thereof.Reaction Step b)

The compound of the formula II may be converting to its salt eitherafter isolation of the compound of the formula II as a free base insolid form or by addition of a suitable salt forming agent to a solutioncomprising the compound of the formula II.

An example of a suitable salt forming agent is HCl.

In one embodiment of the process of Section A, the present inventionrelates to a process for the production of a compound of formula IIcomprising

a) reacting a compound of formula III

with a compound of formula IV

in the presence of the palladium catalystdi-(triphenylphosphine)palladium(II) chloride; the phosphate base K₃PO₄;water and an inert solvent;

wherein compounds of formula III are used in mass percentages between4.5 (w/w) % and 6.5 (w/w) %;

wherein the palladium catalyst is employed in a ratio of from 0.1 to 1mol %, based on the amount of the compound of formula III;

wherein from 2 to 3 equivalents of phosphate base relative to compoundsof formula III are used;

wherein a mass percentage from 40 (w/w) % to 55 (w/w) % water is presentin the reaction mixture; and

wherein the reaction is carried out at a pH from 11.5 to 12;

to form the compound of formula II.

Section B:

In Section B, the present invention relates to a process for theproduction of a compound of formula I

or a salt thereof comprisingc) reacting a compound of formula II

or a salt thereof;with a compound of formula V

or a salt thereof;at elevated temperature in the presence of a base and an inert dipolaraprotic solvent;wherein the base is (M₂)OC(R)₃, wherein M₂ is sodium or potassium andeach R independently is C₁₋₆alkyl or two R together with the carbon atomthey are bound to form C₄-C₆cycloalkyl, or the base is a hydroxide base;to form the compound of formula I; andd) optionally converting the compound of formula I to a salt thereof.Reaction Step c)

The compound of formula II can be made as described in Section A or e.g.according to WO2004/022556A1. In one embodiment of the process ofSection B the compound of formula II is used in free base form.

The compound of formula V is commercially readily available. In oneembodiment of the process of Section B the compound of formula V is usedin free base form.

In the process of Section B, compounds of formula II can be usedtypically in mass percentages of between 1 (w/w) % and 15 (w/w) %. Morepreferably, compounds of formula II are used in mass percentages ofbetween 3 (w/w) % and 10 (w/w) %. Even more preferably, compounds offormula II are used in mass percentages of between 5 (w/w) % and 9 (w/w)%; e.g. 7.9 (w/w) %.

In the process of Section B, compounds of formula V are typically usedin equimolar amounts or in excess relative to compounds of formula II,preferably in an up to 3-fold excess, especially in an up to 2-foldexcess, more especially in an up to 1.1-fold to 1.5-fold excess. In oneembodiment, compounds of formula V are used in an about 1.3-fold excess.

In one embodiment of the process of Section B, the base is (M₂)OC(R)₃,wherein M₂ is sodium or potassium and each R independently is C₁₋₆alkylor two R together with the carbon atom they are bound to formC₄₋₈cycloalkyl. In one embodiment, the base is (M₂)OC(R)₃, wherein M₂ issodium or potassium and each R independently is C₁₋₄alkyl. In oneembodiment, the base is (M₂)OC(R)₃, wherein M₂ is sodium or potassiumand each R independently is C₁₋₂alkyl. In one embodiment, the base issodium tert-butanolate or potassium tert-butanolate. In one embodiment,the base is potassium tert-butanolate.

In one embodiment of the process of Section B, the base is a hydroxybase, e.g. NaOH or KOH.

Suitable amounts of base for the process of Section B are, for example,from 1 to 2 equivalents, especially from 1 to 1.5 equivalents relativeto compounds of formula II. In one embodiment, about 1.1 equivalentsrelative to compounds of formula II are used. It is noted that whensalts of compounds of formula II are used, e.g. a hydrochloride salt, anappropriate higher amount of base will become necessary for performingthe process.

Suitable inert dipolar aprotic solvents for the process of Section B aree.g. dimethylsulfoxide (DMSO), dimethylacetamide (DMAC),dimethylformamide (DMF) or N-methylpyrrolidone (NMP). In one embodiment,the dipolar aprotic solvent is DMSO, typically in a mass percentage ofabout 75-90 (w/w) % of the reaction mixture.

The reaction mixture for the process of Section B may further comprisean inert lipophilic co-solvent having a boiling point above 100° C.,preferably toluene or xylene. In one embodiment, the reaction mixturecomprises a DMSO/toluene solvent/co-solvent mixture, said mixturetypically present in a mass percentage of about 70-85 (w/w) % with aDMSO/toluene ratio of from 5:0.1 to 2:3 by weight, preferably in a ratioof about 3:2 by weight.

In the process of Section B additional solvents may be used, e.g. if thealcoholate base is added as a solution, such as e.g. in tetrahydrofuranesolution. In one embodiment, tetrahydrofurane is used as the solvent forthe base. Said additionally added solvent may be distilled off beforeany or any substantive formation of compounds of formula I takes place,e.g. before the intended elevated temperature for performing the processof Section B is reached, typically between 80° C. and 130° C., and/orbefore addition of compounds of formula II.

The process of Section B is typically carried out substantiallywater-free. In one embodiment, the reaction according to the inventionis carried out in the presence of maximally about 5 mol % water relativeto compounds of formula II. A typical way to remove water from thereaction mixture is distillation after base addition and/or before theintended elevated temperature for performing the process of Section B isreached.

The process of Section B is carried out at elevated temperature;preferably in a temperature range from 80° C. to 130° C., especially ina temperature range from 90° C. to 120° C., more especially in atemperature range from 100° C. to 105° C.

The reaction time of the process of Section B is generally from 0.5 to24 hours, preferably from 1 to 10 hours, especially from 2 to 5 hours.

The process of Section B may be carried out in an inert gas atmosphere.For example, nitrogen or argon is used as inert gas.

The process of Section B can be carried out at normal pressure, but isnot limited to.

In the process described in WO2004/022556A1, the base is added in anamount of 1.2 equivalents relative to compounds of formula II tocompounds of formula V. Then the compound of formula II is added to thereaction mixture. There is no further addition of base to the reactionmixture. With such procedural steps, the full amount of base (i.e. 1.2equivalents) is already present when compound of formula II react withcompounds of formula V, i.e. the base is not added gradually.

It is an important finding of the invention that yield and side-productprofile are improved when less base is initially present and when thebase is gradually added.

Consequently, embodiment B1 of the process of Section B is a process forthe production of a compound of formula I or a salt thereof comprising

c) reacting a compound of formula II or a salt thereof with a compoundof formula V or a salt thereof;

at elevated temperature in the presence of a base and an inert dipolaraprotic solvent;

wherein the base is (M₂)OC(R)₃, wherein M₂ is sodium or potassium andeach R independently is C₁₋₆alkyl or two R together with the carbon atomthey are bound to form C₄₋₆cycloalkyl, or the base is a hydroxide base;

and wherein the base is gradually added to the reaction mixture;

to form the compound of formula I; and

d) optionally converting the compound of formula I to a salt thereof.

One way to carry out embodiment B1 is e.g. the formation of a mixturecomprising compounds of formula II or salts thereof and compounds offormula V or salts thereof, wherein no base is present; and adding thebase to said mixture with a relatively low flow rate.

In one embodiment of embodiment B1, in step c):

c1) a mixture is formed, which comprises the compound of formula II orthe salt thereof; the compound of formula V or the salt thereof; andmaximally about 0.5 equivalents of the base relative to compounds offormula II; and

c2) base is gradually added to said mixture;

In one embodiment of embodiment B1, in step c1) the mixture comprisesmaximally about 0.3 equivalents, preferably maximally about 0.1equivalents, of the base relative to compounds of formula II.

In one embodiment, in step c1) the mixture comprises substantially nobase.

In one embodiment, in step c1) the mixture comprises no base.

In one embodiment of embodiment B1, in step c2) base is added graduallyby (i) adding with a flow rate of maximally about 3.8 mol % relative tocompounds of formula II per minute until about 1.1 equivalents relativeto compounds of formula II are added to the mixture or by (ii) addingportion-wise wherein the initial portion is maximally 0.5 equivalents,preferably 0.25 equivalents, relative to compounds of formula II.

In one embodiment of embodiment B1, in step c2) base is added graduallyby adding with a flow rate of maximally about 1.3 mol % relative tocompounds of formula II per minute until about 1.1 equivalents relativeto compounds of formula II are added to the mixture.

In one embodiment of embodiment B1, in step c2) base is added graduallyby adding with a flow rate that the added base is rapidly consumed forthe formation of the compound of formula I and an inorganic salt, e.g.potassium chloride, preferably, but not limited to, until the sum ofbase from step c1) and c2) is about 1.1 equivalents relative tocompounds of formula II.

Reaction Step d)

The compound of the formula I may be converting to its salt either afterisolation of the compound of the formula I as a free base in solid formor by addition of a suitable salt forming agent to a solution comprisingthe compound of the formula I.

An example of a suitable salt forming agent is fumaric acid.

In one embodiment, fumaric acid is added directly to the reactionmixture of step c), generally after formation of the compounds offormula I and a hydrolytic work-up.

In one embodiment of the process of Section B, the present inventionrelates to a process for the production of a compound of formula I or asalt thereof comprising

c) reacting a compound of formula II with a compound of formula Vat atemperature range from 80° C. to 130° C. in the presence of 1 to 1.5equivalents of base relative to compounds of formula II; and an inertdipolar aprotic solvent; wherein the base is selected from sodiumtert-butanolate and potassium tert-butanolate; and whereinc1) a mixture is formed, which comprises the compound of formula II; thecompound of formula V; and no base; andc2) the base is added to said mixture with a flow rate of maximallyabout 3.8 mol % relative to compounds of formula II per minute untilabout 1.1 equivalents relative to compounds of formula II are added tothe mixture;to form the compound of formula I; andd) optionally converting the compound of formula I to a salt thereof.

The following non-limiting examples are illustrative of the disclosure.

REFERENCE EXAMPLE A1 Preparation/Characterization of free base of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form (Form A)

About 8 mg of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane infree base form dissolved in 0.2 ml methanol was dried in vacuum at 40°C. for >5 hours. After drying, acetonitrile was added to the solidresidue and the mixture was heated to 40° C. and vortexed for about 2hours. The mixture was dried and the remaining solid was analyzed byXPRD.

Following this method, a pattern as shown in FIG. 7A (Form A) can beobtained.

Form A of the free base shows low solubility in aqueous media (0.05mg/ml).

It is hygroscopic: when tested, Loss on drying (LOD) of a sample was0.1% and moisture gain was 2% at 93% relative humidity (RH).

Its melting point was determined by heating at 2° C./minute to be 106°C. (onset) with subsequent decomposition.

REFERENCE EXAMPLE A2 Preparation/Characterization of free base of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form (Form B)

About 8 mg of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane infree base form dissolved in 0.2 ml methanol was dried in vacuum at 40°C. for >5 hours. After drying, ethanol was added to the solid residueand the mixture was heated to 40° C. and vortexed for about 2 hours. Themixture was dried and the remaining solid was analyzed by XPRD (see FIG.7B, Form B).

The same experiment was performed using ethanol or isopropanol assolvent. Basically the same XPRD pattern was obtained. As all threesolid forms gained an XPRD pattern as described under Reference ExampleA1 upon further drying, it was concluded that this new form is analcohol solvate with low association temperature.

EXAMPLE 1 Preparation of mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form

500 mg of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane infree base form were suspended in 20 ml isopropyl alcohol. Astoichiometric amount of fumaric acid was added. The resulting solutionwas stirred at ambient temperature for 14 hours. The precipitate wascollected by filtration and analyzed by proton-NMR and XRPD (see FIG.1). Yield was 85%. Analysis of proton-NMR confirmed salt formation, abase/acid ratio of about 1:1 and the fact that the salt was not asolvate.

EXAMPLE 1.1 Preparation of mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form by seeded crystallization

a) Preparation

7.3 g mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane(purity >98%; prepared as described e.g. in Example 13.2) was dissolvedin ethanol (42.9 g)/isopropanol (8.5 g)/water (7.2 g) at about 50° C.,clarified by filtration and added at this temperature gradually over aperiod of about 8 hours to filtered tertiary-butylmethylether (118.4 g)at a temperature of about 50° C. After about 25% of the filtrate wasadded, an ultrasonificated suspension of seed crystals of themono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane (6mg, prepared e.g. as described in Example 13.2) in isopropanol (0.1 ml)was added to induce crystallization. The product suspension wasmaintained for another 1 hour at 50° C. and cooled to 0° C. within 8hours. After another 1 hour at this temperature the solids were isolatedby filtration, washed with isopropanol/tertiary-butylmethylether (40 ml,1:1 mixture) and dried at about 50° C. under reduced pressure to yieldthe mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane(5.85 g; 81% of theory; purity >99.5%).

b) Characterization: Particle Size Measurements by Fraunhofer LightDiffraction

Result:

Mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form prepared as described according to Example 1.1 wastested. The following values were obtained: X₁₀=5.6±0.5 μm; X₅₀=26.8±1.3μm and X₉₀=77.3±3.3 μm (N=8).

Procedure:

To about 0.5 g of test substance add some drops of the dispersing aid(1% Octastat 5000 (Octel Corp.) in white spirit (Sangajol, SchweizerhallChemie)). Mix intensively on a vortex mixer, in order to wet thesubstance thoroughly and to form a smooth and homogeneous paste. Dilutethe paste with white spirit to a final volume of 3-6 ml and mix thedispersion again. Determine the cumulative volume distribution using alaser diffraction instrument, e.g. determine the particle sizes at theundersize values of 10%, 50% and 90% (x₁₀, x₅₀, x₉₀). Measuring device:Sympatec HELOS (Sympatec GmbH; focal length: 500 mm, opticalconcentration ≧5%, duration of measurement: 40 sec).

Dispersion device: Suspension cell (QUIXEL, Sympatec GmbH).

EXAMPLE 2 Preparation of mono-maleate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form

500 mg of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane infree base form were suspended in 5 ml acetonitrile. A stoichiometricamount of maleic acid was added. The resulting solution was stirred atambient temperature for 14 hours. The precipitate was collected byfiltration and analyzed by proton-NMR and XRPD (see FIG. 2). Yield was63%. Analysis of proton-NMR confirmed salt formation, a base/acid ratioof about 1:1 and the fact that the salt was not a solvate.

EXAMPLE 3 Preparation of mono-hydrochloride salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form

A 1 L reactor, equipped with a mechanical stirrer, digital thermometer,nitrogen inlet-outlet, reflux condenser and heating mantle was chargedwith 14.4 g (R)-3-quinuclidinol, 176 g (160 mL) dimethylsulfoxide and69.5 g (78 mL) 20 wt % potassium tert-butoxide in tetrahydrofuran. Themixture was stirred at 23° C. for 15 minutes and then heated to 95-110°C. over a period of 1 hour to distill off about 40 mL oftetrahydrofuran. Distilling was continued at 110° C. for 30 minutes. Themixture was cooled to 90° C. over a period of 20 minutes. Portionwise,21 g 5-chloro-2-p-tolylpyridine was added. 11 g (20 mL)dimethylsulfoxide was added. The reaction mixture was heated to 100° C.over a period of 20 minutes and kept at said temperature for 3 hours.The mixture was cooled to 15° C. over a period of 1 hour.

370 g (500 mL) tert-butyl methyl ether was added. 250 g water was addedover a period of 30 minutes, while maintaining the temperature below 25°C. The mixture was stirred for 30 minutes. The layers were separated anda solution of 102 g 20% (v/v) aqueous sodium chloride was added to theorganic layer. The mixture was stirred for 15 minutes and the layerswere separated. The organic layer was filtered.

A 1 L reactor, equipped with a mechanical stirrer, digital thermometer,addition funnel, nitrogen inlet-outlet, reflux condenser and heatingmantle was charged with the above organic layer. 109 g (120 mL)peroxide-free 2-propanol was added. A solution of 16.5 g (17.8 mL) 5.3 NHCl in 2-propanol was added over a period of 40 minutes. The mixture washeated to 53° C. and stirred for 30 minutes. The mixture was cooled to23° C. over a period of 30 minutes and stirred for 1 hour. The solid wascollected by filtration and washed with a solution of 2×37 g (50 mL) of1% (v/v) peroxide-free 2-propanol/tert-butyl methyl ether. The solid wasdried at 55° C. under reduced pressure to afford 20.9 g of themono-hydrochloride salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane.The material was analyzed by XRPD (see FIG. 3).

EXAMPLE 4.1 Preparation of mono-phosphate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form (Form A)

500 mg of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane infree base form were suspended in 20 ml ethanol. A stoichiometric amountof phosphoric acid was added. The resulting solution was stirred atambient temperature for 14 hours. The precipitate was collected byfiltration and analyzed by proton-NMR and XRPD (see FIG. 4A, Form A).Yield was 77%. Analysis of proton-NMR confirmed salt formation and thefact that the salt was not a solvate. Elemental analysis was performedconfirming a base/acid ratio of about 1:1 (C, 57.9% (58.1%); H, 6.7%(6.4%); N, 7.1% (7.1%); and P, 7.7% (7.9%); theoretical values inbrackets).

EXAMPLE 4.2 Preparation of phosphate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form (Form B)

About 2.3 mg of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane infree base form was dissolved in 0.15 ml ethanol. A stoichiometric amountof phosphoric acid was added. The mixture was dried in vacuum at 40° C.for >5 hours. After drying, 0.1 ml ethanol and 0.05 ml water were added.The mixture was heated to 40° C. and vortexed for about 2 hours. Themixture was dried and the remaining solid was analyzed by XPRD (see FIG.4B, Form B).

EXAMPLE 4.3 Preparation of phosphate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form (Form C)

200 mg of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane infree base form was suspended in 2 ml ethanol. One-third of thestoichiometric amount of phosphoric acid was added. The slurry obtainedwas stirred at ambient temperature and held for 14 hours. Solids wereseparated by filtration and analyzed by XPRD (see FIG. 4C, Form C).

EXAMPLE 5.1 Preparation of mono-succinate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form (Form A)

500 mg of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane infree base form were suspended in 5 ml ethanol. A stoichiometric amountof succinic acid was added. The resulting solution was stirred atambient temperature for 14 hours. The precipitate was collected byfiltration and analyzed by proton-NMR and XRPD (see FIG. 5, Form A).Yield was 64%. Analysis of proton-NMR confirmed salt formation, abase/acid ratio of about 1:1 and the fact that the salt was not asolvate.

EXAMPLE 5.2 Preparation of anhydrous mono-succinate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form

When the Form A of the mono-succinate salt (see Example 5.1) wassubjected to heat (under nitrogen) from 25° C. to 115° C., an anhydrousform of mono-succinate salt was observed and analyzed by XRPD (see FIG.5, Form B).

EXAMPLE 6 Preparation of mono-malonate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form

500 mg of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanewere suspended in 5 ml acetonitrile. A stoichiometric amount of malonicacid was added. The resulting solution was stirred at ambienttemperature for 14 hours. The precipitate was collected by filtrationand analyzed by proton-NMR and XRPD (see FIG. 6). Yield was 77%.Analysis of proton-NMR confirmed salt formation, a base/acid ratio ofabout 1:1 and the fact that the salt was not a solvate.

EXAMPLE 7 Comparison of Physico-Chemical Parameters of Salt Forms

Hygro- Decom- Aqueous Initial scopy position Known solubility water @85% temper- Multiple [mg/ml] content RH m.p. ature forms Free Base 0.050.1 ~2 106 224 Yes Fumarate >30 <0.5 0.5 164 207 No Maleate >30 <0.1 0.3154 207 No Hydrochloride, >30 ~5 ~5 240 262 Yes Form A Phosphate, >30~0.5 0.2 222 222 Yes Form A Succinate 2-15 ~4.5 0.3 113 222 YesMalonate >30 ~0 1.3 140 148 No

EXAMPLE 8 Hard Capsules

Hard gelatin capsules, each comprising as active ingredient 0.5, 5 or 25mg of the mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanecan be prepared as follows:

% (w/w) % (w/w) % (w/w) for 0.5 mg for 5 mg for 25 mg Ingredient forcapsule fill capsules capsules capsules Mono-fumarate of (R)-3-(6-(4-0.46 4.65 23.23 methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane Lactose monohydrate 65.24 61.05 42.47Microcrystalline cellulose 25.00 25.00 25.00 Hypromellose 2.50 2.50 2.50Sodium croscarmellose 6.00 6.00 6.00 Colloidal silicon dioxide 0.30 0.300.30 Magnesium stearate 0.50 0.50 0.50 Purified water* q.s. q.s. q.s.*removed during processing

Preparation process: Mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane,lactose monohydrate, microcrystalline cellulose, a portion of sodiumcroscarmellose and hypromellose are dry mixed in a high shear mixerbowl, and granulating fluid (purified water) added. Once the granulationis complete, the wet granules are dried in a fluid bed drier and the drygranules are milled. The remaining sodium croscarmellose and colloidalsilicon dioxide are passed through a suitable sieve and added to thedried granular material and blended in a suitable blending shell. Thisis achieved by co-sieving the sodium croscarmellose and the colloidalsilicon dioxide with a portion of the milled granules through a suitablesieve into the blending shell. Similarly, the required amount of sievedmagnesium stearate is added to the bulk granule and then mixed in thesame blending shell. This final blend is encapsulated into capsulesusing automated equipment. Weight ratio of capsule fill to empty capsuleshells is 2:1.

EXAMPLE 9 Tablets EXAMPLE 9.1 Film-Coated Tablet

Film-coated tablets containing e.g. 0.5 mg of the mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanemay be prepared as follows:

Preparation of Pre-Mix:

Weigh-in mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane(e.g. approx. 0.7%) and maize starch (e.g. approx. 13%), mix in a tumbleblender (approx 100-300 rotations), pass through a sieve of approx.0.25-1.0 mm mesh-size. Mix in a tumble blender (approx. 100-300rotations).

Preparation of Final Blend:

To above pre-mix add microcrystalline cellulose (e.g. approx. 25%),sprayed lactose (e.g. approx. 68%), sodium-carboxymethylcellulose XL(e.g. approx. 2%) and Aerosil (e.g. approx. 0.5%) and mix in a tumbleblender (approx. 100-300 rotations). Pass this mixture through a sieveof approx. 0.5-1.0 mm mesh-size and mix again (approx. 100-300rotations).

Add the sodium-stearyl-fumarate (e.g. approx. 1.5%) through a handsieveat approx. 0.5-1.0 mm mesh-size and mix in a tumble blender (approx.30-150 rotations).

Compression:

On a rotary press compress the above final blend to cores of approx. 100mg, using the dosage specific tooling (e.g. approx. 6 mm, round,curved).

Coating:

Prepare a suspension in water with basic coating premixes black, red,yellow and/or white. Coat the above obtained cores in a perforatedcoating pan, and dry.

EXAMPLE 9.2 Bilayer Film-Coated Tablet

Bilayer film-coated tablets containing e.g. 2.5 mg of the mono-fumarateof (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanemay be prepared as follows:

Final Active Blend:

Weigh-in mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanecoarse (e.g. approx. 15.5%), microcrystalline cellulose (e.g. approx.25%), sprayed lactose (e.g. approx. 53%), sodium-carboxymethylcelluloseXL (e.g. approx. 3%) and Aerosil (e.g. approx. 0.5%) and mix in a tumbleblender (approx 100-300 rotations). Pass this mixture through a sieve ofapprox. 0.5-1.0 mm mesh-size and mix again (approx 100-300 rotations).

Add the Na-stearyl-fumarate (e.g. approx. 3%) through a handsieve atapprox. 0.5-10 mm and mix in a tumble blender (approx 30-150 rotations).

Final Placebo Blend:

Weigh-in microcrystalline cellulose (e.g. approx. 26%), sprayed lactose(e.g. approx. 69%), sodium-carboxymethylcellulose XL (e.g. approx. 1.9%)and Aerosil (e.g. approx. 0.5%) and mix in a tumble blender (approx100-300 rotations). Pass this mixture through a sieve of approx. 0.5-1.0mm mesh-size and mix again (approx 100-300 rotations).

Add the sodium-stearyl-fumarate (e.g. approx. 3%) through a handsieve atapprox. 0.5-1.0 mm and mix in a tumble blender (approx 30-150rotations).

Compression:

On a rotary press compress the above final blends to a bilayertablet-core of approx. 100 mg with one placebo layer (approx. 77.5 mg)and one active layer (approx. 22.5 mg), using the dosage specifictooling (e.g. approx. 6 mm, round, curved).

Coating:

Prepare a suspension in water with basic coating premixes black, red,yellow and/or white. Coat the above obtained cores in a perforatedcoating pan, and dry.

EXAMPLE 9.3 Film-Coated Tablet

Film-coated tablets containing e.g. 50 mg of the mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanemay be prepared as follows:

Final Blend:

Weigh-in mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanecoarse (e.g. approx. 15.5%), microcrystalline cellulose (e.g. approx.25%), sprayed lactose (e.g. approx. 53%), sodium-carboxymethylcelluloseXL (e.g. approx. 3%) and Aerosil (e.g. approx. 0.5%) and mix in a tumbleblender (approx. 100-300 rotations). Pass this mixture through a sieveof approx. 0.5-1.0 mm mesh-size and mix again (approx. 100-300rotations).

Add the sodium-stearyl-fumarate (e.g. approx. 3%) through a handsieve atapprox. 0.5-10 mm and mix in a tumble blender (approx. 30-150rotations).

Compression:

Compress the above final blend on a rotary press to cores, using thedosage specific tooling (e.g. approx. 15*5.9 mm, round, curved).

Coating:

Prepare a suspension in water with basic coating premixes black, red,yellow and/or white. Coat the above obtained cores in a perforatedcoating pan, and dry.

EXAMPLE 10 Biological Data

The usefulness of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane inits various forms, e.g. in free base form (Compound A) or inmono-fumarate salt form (Compound B) in the treatment of theabove-mentioned disorders can be confirmed in a range of standard testsincluding those indicated below.

10.1. In-vitro Tests: Selectivity of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octaneagainst α4β2-nAChR

Based on the activity/selectivity data shown below it is concluded thatsaid compound is a selective agonist at the α7-nAChR.

α7-nAChR activity Efficacy Potency compared to EC₅₀ epibatidineα4β2-nAChR activity Compound (nM) (100%) IC₅₀ (nM) EC₅₀ (nM) foldselectivity A 35 75 5598 >100′000 164Assay:

To assess α7-nAChR activity, a functional assay was employed using GH3cells that recombinantly expressed human α7-nAChR. 40000 cells per wellwere seeded 48 h prior to the experiment on black 96-well plates(Costar) and incubated at 37° C. in a humidified atmosphere (5% CO₂/95%air). On the day of the experiment, medium was removed by flicking theplates and replaced with 0.1 ml growth medium containing 0.002 mMFluo-4, (Molecular Probes) in the presence of 2.5 mM probenecid (Sigma).The cells were incubated at 37° C. in a humidified atmosphere (5%CO₂/95% air) for 1 h. Plates were flicked to remove excess of Fluo-4,washed twice with Hepes-buffered salt solution (HBSS, in mM: NaCl 130,KCl 5.4, CaCl₂ 2, MgSO₄ 0.8, NaH₂PO₄ 0.9, glucose 25, Hepes 20, pH 7.4;HBS) and refilled with 0.1 ml of HBS containing antagonist whenappropriate. The incubation in the presence of the antagonist lasted 3-5minutes. Plates were placed in the cell plate stage of a FLIPR device(fluorimetric imaging plate reader, Molecular Devices, Sunnyvale,Calif., USA). After recording of the baseline (laser: excitation 488 nmat 1 W, CCD camera opening of 0.4 seconds) the agonists (0.05 ml) wereadded to the cell plate using the FLIPR 96-tip pipettor whilesimultaneously recording the fluorescence. Calcium kinetic data werenormalized to the maximal fitted response induced by epibatidine, whichis a full agonist at α7-nAChR. Four parameter Hill equations were fittedto the concentration-response. Values of Emax (maximal effect in %compared to the epibatidine response) and EC₅₀ (concentration producinghalf the maximal effect in μM) were derived from this fit.

Assay described in: D Feuerbach et al, Neuropharmacology (2005), 48,215-227.

To assess the activity of the compound of the invention on the humanneuronal nAChR α4β2, a similar functional assay is carried out using ahuman epithelial cell line stably expressing the human α4β2 subtype(Michelmore et al, Naunyn-Schmiedeberg's Arch. Pharmacol. (2002) 366,235).

10.2. In-Vivo Preclinical Tests 10.2.1. Oral bioavailability and brainpenetration of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane inMice

Based on the pharmacokinetic data shown below it is concluded that thebrain concentration of said compound in mice is beyond (or at leastequal) to the compound's EC₅₀ at the α7-nAChR for at least 4 hoursfollowing an acute oral dose of 30 μmol/kg of the compound in free baseform.

Compound A:

Ratio Time Plasma Brain Brain/ Administration (hour) (pmoles/ml ± SD)(pmoles/g ± SD) plasma 30 μmol/kg p.o. 0.25 573 ± 234  4631 ± 1717 8 30μmol/kg p.o. 0.5 559 ± 143 11430 ± 3441 20 30 μmol/kg p.o. 1 322 ± 13514948 ± 4716 46 30 μmol/kg p.o. 4 20 ± 16 1272 ± 715 62 30 μmol/kg p.o.8 3.4 ± 0.8  58 ± 27 17 30 μmol/kg p.o. 24 — — —Assay:

Compounds were orally (30 μmol/kg) administered. Male mice (30-35 g, OF1/ICstrain) were sacrificed at indicated time points after oraladministration. Trunk-blood was collected in EDTA-containing tubes andthe brain was removed and immediately frozen on dry ice. To 100 μlplasma 10 μl internal standard (1.0 μmol of a compound with solubilityand ionization properties similar to test compounds) was added andextracted three times with 500 μl dichloromethane. The combined extractswere then dried under a stream of nitrogen and re-dissolved in 100 μlacetonitrile/water (70% acetonitrile). Brains were weighed andhomogenized in water (1:5 w/v). Two 100 μl aliquots of eachhomogenate+10 μl of internal standard (same standard as used for theplasma samples) were extracted three times with 500 μl dichloromethaneand further processed as the plasma samples. Samples were separated onBeckmann high-performance liquid chromatography equipment system with anautosampler (Gilson 233XL). A 10 min linear gradient (10-70%) ofacetonitrile containing 0.5% (v/v) formic acid was used to elute thecompounds from Nucleosil CC-125/2 C18 reversed phase (Machery & Nagel)column.

The limit of detection (LOD), defined as the lowest concentration of theextracted standard sample with a signal to noise ratio of ˜3.

10.2.2. Functional read-out of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane inMice Social Recognition Test

Based on the functional in-vivo data shown below it is concluded thatoral dosing of said compound at relevant concentrations leads to aspecific effect associated with α7-nAChR (i.e. cognition enhancement inthe Social Recognition Test in mouse).

Reduction in time scrutinizing in % ± Dose Compound SEM at 24 h in mg/kgA 36 ± 6 0.3Assay:

Social interactions between two experimental animals are influenced bytheir degree of familiarity: the better they know each other, the lesstime they spend on mutual scrutiny at each meeting. In agreement withpublished data in rats (Mondadori et al., 1993) we have observed (i)that an adult mouse shows a shortened scrutiny of a young conspecific ifthe two mice are brought together again within a short time interval(e.g. 1 hour), (ii) that this curtailment is attributable to memoryprocesses: it does not occur if the familiar young partner is replacedby a strange (unfamiliar) young mouse on the second occasion and (iii)that the adult mouse's recollection of the previously scrutinizedjuvenile partner fades with the elapsed time, i.e., after 24 h, scrutinytakes just about as long as at the first encounter. Memory enhancingagents (i.e. oxiracetam) facilitate learning to the extent that thepreviously met (familiar) partner is still remembered after 24 h,whereas in vehicle treated control animals the memory usually fadesafter less than 1 hour (Thor and Holloway, 1982) or after 2-3 hours.

Baseline-test: Pairs consisting of one adult and one young mouse wereassigned at random to the experimental and control groups. In each paironly the adult mouse was orally treated 1 hour before the trial witheither vehicle or the test compound. The duration of active contacts ofthe adult mouse with the young mouse was manually recorded over a periodof 3 min, including the following behavioural, approach-related items:sniffing, nosing, grooming, licking, pawing and playing, anogenitalexploration and orientation toward the young mouse; orientation,thereby, was defined as tip of nose of the adult mouse less thanapproximately 1 cm distant from the young mouse's body.

Re-test: Twenty-four hours after the baseline-test, the adults in eachtreatment group were confronted again with the previously encountered(familiar) partner, whereas the half of the adult animals were puttogether with the previously encountered (familiar) partner and theother half with another (unfamiliar) young mouse. Again the duration ofactive approach-behaviours was recorded during a 3-min period. Prior tore-test no oral injection was given. In the table the reduction in timescrutinizing the familiar partner at time 24 compared with the familiarpartner at time 0 minutes is given (value of zero would signify noreduction).

10.2.3. Oral bioavailability of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane inDogs

Based on the pharmacokinetic data shown below it is concluded that thecompound reaches significant blood levels in dogs following an acuteoral dose of 1.4 μmol/kg of the compound in fumarate salt form.

Compound B:

Time Plasma Administration (hour) (pmoles/ml ± SD) 1.4 μmol/kg p.o. 0.2514.7 ± 1.1  1.4 μmol/kg p.o. 0.5 49.4 ± 21.9 1.4 μmol/kg p.o. 1 67.6 ±22.6 1.4 μmol/kg p.o. 2 75.2 ± 36.8 1.4 μmol/kg p.o. 4 27.5 ± 13.3 1.4μmol/kg p.o. 8 8.1 ± 3.0 1.4 μmol/kg p.o. 24 0.8 ± 0.7Assay:

The compound was given to N=3 male beagle dogs in tritiated form:

The concentration of the compound in blood was determined by LC-RID. Theprocedure involved the addition of 5 μg of the compound as internalstandard (200 μL of solution containing 25 μg/mL of the compound) to 1mL of blood. After further addition of 1 mL of water, 0.1 mL of bufferpH 9 and 4 mL of tert-butylmethylether, the samples were shaken for 30min and centrifuged (4000 g for 10 min at 22° C.). The organic phase wastransferred into a tube and evaporated in a Speedvac. The residue wasreconstituted in 250 μL of mobile phase-water (80:20 v/v) followed by 75μL of n-hexane and transferred into an autosampler vial. Aftercentrifugation (13,000 g for 2 min at 22° C.), the hexane layer waspipetted off and discarded, 200 μL of the remainder was injected onto anRP18 column (Waters XTerra, 5 μm, 3.9×150 mm at 40° C.) to separate thecompound from potential metabolites and endogenous compounds. The mobilephase of ammonium acetate (10 mM:0.1% v/v TFA-acetonitrile, 58:42 v/v)was used at a flow rate of 1.0 mL/min. The effluent was monitored by aUV-detector set at 261 nm. The peak corresponding to the unchangedcompound was collected in a polyethylene vial by a fraction collector(SuperFrac, Pharmacia LKB) and analyzed for radioactivity. Theconcentration of the compound in each sample was calculated from theratio of the amount of radioactivity in the eluate fraction to the areaof the ultraviolet absorbance of the non-radiolabeled the compound, thatwas used as the internal standard.

EXAMPLE 10.2.4 Pharmacokinetics of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane inRats

Please note that dosing information in this Example 10.2.4 is givenrelative to the free form,(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane,and is independent from the salt forming agent. If a salt forming agentis used (e.g. fumarate), a corresponding higher amount of the salt willbe used to achieve the intended dosing.

Based on the pharmacokinetic data shown below:

After acute oral dosing of 10 mg/kg(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane inmono-fumarate salt form, a Cmax of the free form in plasma of 161±53ng/ml was reached at 0.25-0.5 h. The AUClast amounted to 249±42 h·ng/ml.After acute oral dosing of 10 mg/kg(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane infree form, a Cmax of the free form in plasma of 112±40 ng/ml was reachedat 0.25-0.5 h. The AUClast amounted to 200±62 h·ng/ml.

Pharmacokinetics of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane inWistar rats after oral administration of 10 mg/kg of the compound inmono-fumarate salt form (Compound B) and in free base form (Compound A)were assessed.

Both compounds were dissolved in Klucel™ (0.5% in water) and were orallyadministered by gavage (5 ml/kg) to conscious rats (n=8, cross-overdesign).

K3-EDTA blood (˜0.2 ml) was collected by puncture of a sublingual veinunder light isoflurane anesthesia at the following time points: 0.25,0.5, 1, 2, 3, 4, 6, 8, 24 h post dose. Immediately after sampling, bloodsamples were put on ice and were processed to plasma by centrifugationat 4° C. within 15 min after sampling (1000 g, 10 min, 4° C.) to obtain˜100 μl plasma/sample. All plasma samples were stored at −80° C. untilanalysis. Since the PK study was performed in a cross-over design, arecovery period of approximately 2 weeks took place before the nexttreatment/blood sampling was performed.

The determination of compounds in plasma was done by LC-MS/MS usingelectrospray ionization.

a. Concentrations (nq/ml) and derived pharmacokinetic parameters of(R)-3-(6-(4- methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanein plasma of male Wistar rats following oral administration of 10 mg/kgfree base Phase 1 1 1 1 2 2 2 Rat Rat Rat Rat Rat Rat Rat 01 02 03 04 0506 07 Time (h)  0.25 58.8 89.6 83.0 79.4 105 188     49.0  0.5 34.8 51.264.5 94.8 119 122     117  1 20.1 31.4 63.9 36.0 65.8 83.6   87.0  2 6.912.6 51.7 16.2 43.2 46.9   42.2  3 5.31 8.38 26.3  7.84 23.0 34.4   18.4 4 3.94 3.99 18.2  4.54 8.63 21.1   13.8  6 4.87 1.81 6.62  1.27 5.324.38  4.59  8 6.62 0.812 2.46  1.32 3.67 1.54  2.25 24 1.40 2.44 0.547 1.02 0*  0.632 0.248 Body weight (kg)^(b) 0.297 0.277 0.288   0.2710.309 0.318 0.315 Dose (mg/kg) 10.1 10.2 9.76 10.1 9.88 9.96  10.0 Tmax(h) 0.25 0.25 0.25  0.50 0.50 0.25  0.50 Tlast (h) 24.0 24.0 24.0 24.08.0 24.0   24.0 Cmax (ng/mL) 58.8 89.6 83.0 94.8 119 188     117Cmax/Dose 5.81 8.79 8.50  9.40 12.0 18.9   11.7 (ng/mL)/(mg/kg) AUClast(h·ng/mL) 141 123 238 136   214 296     234 AUClast/Dose 14.0 12.0 24.413.5 21.6 29.7   23.4 (h·ng/mL)/(mg/kg) T1/2 (h) 8.67 nd 5.71 nd 3.24 nd4.54 T1/2 range (h) [6-24] nd [6-24] nd [4-8] nd [6-24] Phase 2 Rat MeanSD CV 08 All All (%) Time (h)  0.25 145 100 46.2 46.3  0.5 65.0 83.534.0 40.7  1 33.8 52.7 25.6 48.5  2 29.9 31.2 17.3 55.5  3 6.20 16.210.9 67.3  4 8.55 10.3 6.66 64.4  6 6.06 4.37 1.90 43.5  8 9.67 3.543.08 86.9 24 0.287 0.822 0.792 96.4 Body weight (kg)^(b) 0.350 — — —Dose (mg/kg) 9.65 10.0 0.184 1.85 Tmax (h) 0.25 0.25 [0.25-0.50]^(a)Tlast (h) 24.0  24.0 [8.0-24.0]^(a) Cmax (ng/mL) 145 112 40.4 36.1Cmax/Dose 15.0 11.3 4.14 36.7 (ng/mL)/(mg/kg) AUClast (h·ng/mL) 236 20061.9 30.6 AUClast/Dose 24.5 20.4 6.43 31.5 (h·ng/mL)/(mg/kg) T1/2 (h)3.67 5.17 2.17 42.1 T1/2 range (h) [6-24] ^(a)Median [range] ^(b)At timeof treatment nd: Not determined due to r² < 0.75 or AUC % extrapolated >30% *Values BLOQ (0.150 ng/mL) were set to 0 for Phoenix PKcalculations.

b. Concentrations (ng/ml) and derived pharmacokinetic parameters of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1- aza-bicyclo[2.2.2]octanein plasma of male Wistar rats following oral administration of 10 mg/kgmono-fumarate. Phase 2 2 2 2 1 1 1 Rat Rat Rat Rat Rat Rat Rat 01 02 0304 05 06 07 Time (h)  0.25 167 162 77.8 89.0 242 204   93.3  0.5 104 13078.4 99.7 143 179   184  1 67.1 88.8 41.3 62.8 83.2 80.8 101  2 27.439.2 37.8 24.6 47.1 37.6 54.8  3 12.4 17.7 25.3 11.7 19.6 20.6 25.1  49.06 10.6 13.3 5.90 9.71 11.8 13.0  6 7.49 3.47 7.63 5.79 4.29  4.244.05  8 2.91 2.35 3.62 2.62 2.46  1.94 2.38 24 0*  0.276 0.210 0.169 0*  1.40 0.162 Body weight (kg)^(b) 0.341 0.315 0.330 0.300 0.268   0.2660.276 Dose (mg/kg) 9.73 9.86 9.95 9.82 9.61  9.69 10.1 Tmax (h) 0.250.25 0.50 0.50 0.25  0.25 0.50 Tlast (h) 8.0 24.0 24.0 24.0 8.0 24.024.0 Cmax (ng/mL) 167 162 78.4 99.7 242 204   184 Cmax/D 17.2 16.4 7.8810.2 25.2 21.1 18.3 (ng/mL)/(mg/kg) AUClast (h·ng/mL) 202 259 212 188269 292   298 AUClast/D 20.8 26.3 21.4 19.2 28.0 30.1 29.6(h·ng/mL)/(mg/kg) T1/2 (h) 2.44 5.02 3.62 3.71 2.02 nd 3.97 T1/2 range(h) [4-8] [6-24] [6-24] [6-24] [4-8] nd [6-24] Phase 1 Rat Mean SD CV 08All All (%) Time (h)  0.25 153    149 58.5 39.4  0.5 138    132 37.428.3  1 94.2  77.4 19.4 25.1  2 42.6  38.9 9.81 25.2  3 23.2  19.5 5.2727.1  4 11.1  10.6 2.39 22.6  6  3.87 5.10 1.66 32.5  8  2.07 2.54 0.52920.8 24  0.344 0.320 0.453 141 Body weight (kg)^(b)  0.290 — — — Dose(mg/kg)  9.77 9.81 0.146 1.49 Tmax (h)  0.25 0.25 [0.25-0.50]^(a) Tlast(h) 24.0   24.0 [8.0-24.0]^(a) Cmax (ng/mL) 153    161 52.9 32.8 Cmax/D15.7  16.5 5.54 33.6 (ng/mL)/(mg/kg) AUClast (h·ng/mL) 272    249 42.216.9 AUClast/D 27.9  25.4 4.30 16.9 (h·ng/mL)/(mg/kg) T1/2 (h)  5.513.76 1.26 40.3 T1/2 range (h) [6-24] ^(a)Median [range] ^(b)At time oftreatment nd: Not determined due to r² < 0.75. *Values BLOQ (0.150ng/mL) were set to 0 for Phoenix PK calculations.

EXAMPLE 11 Preparation of 5-chloro-2-(4-methylphenyl)pyridine (Processaccording to Section A)

Under nitrogen 2,5-dichloro-pyridine (40 g, 270 mmol),4-methylphenylboronic acid (39 g, 289 mmol) andbistriphenylphosphin-palladium(II) dichloride (1.14 g; 1.6 mmol) weresuspended in water (258 g)/THF (117 g) for approx. 30 min at 35-55° C. Asolution of tripotassium phosphate (143.4 g, 676 mmol) in water (143 g)was added at 35-55° C. during approx. 60-120 min and 55° C. wasmaintained for another approx. 30-45 min. More tripotassium phosphate(22.9 g, 108 mmol) in water (22.9 g) was added over a period of approx.30 min and the temperature was raised to 55-60° C. to complete thereaction within another approx. 2 h.

For extractive palladium removal a solution of cysteine (ca. 16 g) inwater (115 g) was added to the reaction mixture at 60-55° C. Afterapprox. 1 h at 55° C. the biphasic reaction mixture was clarified byfiltration over a pad of cellflock filter aid (2-5 g) and a THF/watermixture (110 g/75 g) was used for rinsing. The layers of the combinedfiltrates were separated at 25° C. and the salt containing water layerwas extracted with THF (1×57 g). The combined THF layers were dilutedwith ethanol 94% (195 g) and concentrated by distillation under reducedpressure (300-200 mbar) at a jacket temperature of 45° C. in order toremove the bulk of THF (175-250 g). To the remaining product solutionfurther ethanol (97 g) was added and at 45-55° C. water (565 g) wasgradually added over a period of approx. 60 min to induce and maintaincrystallization. After 30 min the temperature was lowered to approx. 20°C. in approx. 90-120 min and after another hour at that temperature thesolids were collected by filtration, washed with ethanol/water 1:2 anddried under reduced pressure to yield5-chloro-2-(4-methylphenyl)pyridine (52.5 g; 95% of theory; purity>95%;Pd <25 ppm).

EXAMPLE 12 Preparation of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane infree form and fumarate salt form (Process according to Section B)EXAMPLE 12.1 Formation of Free Form

Under nitrogen, to 3R-quinuclidinol (43.8 g, 0.34 mol) in DMSO (792 g)an approx. 20% THF solution of potassium tert-butoxide (210 g, 0.375mol) was added and at approx. 40-45° C. under reduced pressure the THFsolvent was distilled off. The temperature of the reaction mixture wasraised to 90° C. and the solid 5-chloro-2-(4-methylphenyl)pyridine (61.2g, 0.30 mol) was gradually added in at least 4 portions. The temperaturewas raised further to approx. 100-105° C. and after at least another 3hours at this temperature the reaction to(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanewas complete.

Water (150 g) was added to the reaction mixture at 60-25° C. and thetemperature was gradually lowered to approx. 20° C. in approx. 60 minand additional water (210 g) was added. After at least another 2 furtherhours at this temperature the fine solids were collected by filtration,washed successively with DMSO/water (approx. 322 g; 2:1 mixture), water(500 g) and water/ethanol (approx. 500 g; 9:1 mixture) and dried at 60°C. under reduced pressure to yield(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane(56.3 g, 63% of theory).

EXAMPLE 12.2 Formation of Fumarate Salt Form

To a clear solution of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane(39.6 g; 0.135 mol) and fumaric acid (16.4 g, 0.141 mol) in ethanol (330g)/water (21 g) at 65° C. tert.-butylmethylether (142.5 g) was added andthe reaction mixture was cooled to 23° C. in approx. 60 min. Furthertert.-butylmethylether (170.6 g) was added. After at least another 2hours the solids were collected by filtration, washed withethanol/tert.butylmethylether (153 g; 1.1 mixture) and dried at 55-60°C. under reduced pressure to yield(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanehydrogenfumarate (43.8 g, 79% of theory).

EXAMPLE 13 Preparation of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane infree form and fumarate salt form (Process according to Section B1)EXAMPLE 13.1 Formation of Free Form

Under nitrogen to 3R-quinuclidinol (41.4 g, 0.325 mol) in DMSO (320 g) asolution of 5-chloro-2-(4-methylphenyl)pyridine (51 g, 0.250 mol) intoluene (201 g) was added. The temperature was raised gradually toapprox. 100-105° C. while residual water, if any, was removed byrefluxing under reduced pressure at a water trap for ca. 45 min. Over aperiod of approx. 90 min an approx. 20% THF solution of potassiumtert-butoxide (158.8 g, 0.283 mol) was continuously added whilegradually the THF solvent distilled off. After another 2-5 hours atapprox. 100-105° C. the reaction to(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanewas complete.

Water (293 g) was added to the reaction mixture at 60-25° C. The layerswere separated and the toluene layer was washed with water (2×42 g). Thetoluene solution was dried at ca. 60° C. by refluxing under reducedpressure at a water trap for ca. 45-60 min.

EXAMPLE 13.2 Formation of Fumarate Salt Form

To the toluene solution of Example 13.1, at ca. 50-55° C., a slurry offumaric acid (26.1 g, 0.9 eq) in EtOH 94% (22 g) and toluene (97 g) wasgradually added. Further toluene (97 g) was added for rinsing and afteranother ca. 30-60 min at 55° C. the temperature was gradually lowered toapprox. 20° C. in approx. 120-180 min. After at least another 1 hour thesolids were collected by filtration, washed with water saturated toluene(2×104 g) and dried at 60° C. under reduced pressure to yield(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanehydrogenfumarate (84.8 g; 82% of theory, based on amount of5-chloro-2-(4-methylphenyl)pyridine used in Example 13.1).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the XRPD pattern for the mono-fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form

FIG. 2 shows the XRPD pattern for the mono-maleate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form

FIG. 3 shows the XRPD pattern for the mono-hydrochloride salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form

FIGS. 4A, 4B and 4C show the XRPD patterns for Form A, B and C of thephosphate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form

FIGS. 5A and 5B show the XRPD patterns for Form A and B of themono-succinate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form

FIG. 6 shows the XRPD pattern for the mono-malonate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane incrystalline form

FIGS. 7A and 7B show the XRPD patterns for Form A and B of the free baseof (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octanein crystalline form

The invention claimed is:
 1. A pharmaceutical composition, whichcomprises a salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane,wherein said salt is the fumarate, maleate, chloride, phosphate,succinate or malonate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane asactive ingredient; and at least one pharmaceutically acceptable carrier.2. The pharmaceutical composition of claim 1, further comprising one ormore further therapeutic agents as active ingredients and at least onepharmaceutically acceptable carrier.
 3. The pharmaceutical compositionof claim 1, wherein the salt further comprises mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane.4. The pharmaceutical composition of claim 3 in the form of a tabletcomprising (a) a filler; (b) a disintegrant; (c) a lubricant; and (d) agliding agent, wherein the only lubricant present is a lubricantselected from sodium stearyl fumarate, sodium lauryl sulfate, glycerylbehenates, hydrogenated vegetable oils, wax cetyl esters and talc. 5.The pharmaceutical composition of claim 3 in the form of a tabletcomprising (a) up to 10% by weight mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane asactive ingredient; (b) from 1 to 20% by weight maize starch; from 15 to35% by weight microcrystalline cellulose; and from 40 to 75% by weightsprayed lactose; (c) from 0.5 to 5% by weight sodiumcarboxymethylcellulose XL; (d) from 0.5 to 3% by weight sodium stearylfumarate; and (e) from 0.1 to 1% by weight Aerosil.
 6. Thepharmaceutical composition of claim 3 in the form of a tablet comprisingfrom 1 to 10% by weight mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane;wherein the composition comprises an active ingredient layer comprisingthe mono-fumarate and an auxiliary layer being devoid of themono-fumarate; wherein the weight ratio of the active ingredient layerto the auxiliary layer is from 10:90 to 90:10.
 7. The pharmaceuticalcomposition of claim 3 in the form of a tablet comprising from 1 to 10%by weight mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane;wherein the composition comprises an active ingredient layer comprisingthe mono-fumarate and an auxiliary layer being devoid of themono-fumarate; wherein the weight ratio of the active ingredient layerto the auxiliary layer is from 10:90 to 90:10; wherein the activeingredient layer comprises (1a) from 11 to 25% by weight of the activeingredient layer the mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane;(1b) from 15 to 35% by weight of the active ingredient layermicrocrystalline cellulose; and from 40 to 70% by weight of the activeingredient layer sprayed lactose; (1c) from 1 to 5% by weight of theactive ingredient layer sodium carboxymethylcellulose XL; (1d) from 1 to5% by weight of the active ingredient layer sodium stearyl fumarate; and(1e) from 0.1 to 1% by weight of the active ingredient layer Aerosil;and wherein the auxiliary layer comprises (2a) from 10 to 35% by weightof the auxiliary layer microcrystalline cellulose; and from 50 to 75% byweight of the auxiliary layer sprayed lactose; (2b) from 1 to 3% byweight of the auxiliary layer sodium carboxymethylcellulose XL; (2c)from 1 to 5% by weight of the auxiliary layer sodium stearyl fumarate;and (2d) from 0.1 to 1% by weight of the auxiliary layer Aerosil.
 8. Thepharmaceutical composition of claim 1, comprising at least 90 weight %of salt, based on the weight of the composition.
 9. The pharmaceuticalcomposition of claim 3, wherein the composition is in the form of atablet.
 10. A pharmaceutical composition, which comprises a fumaratesalt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane asactive ingredient and at least one pharmaceutically acceptable carrier.11. The pharmaceutical composition of claim 10, wherein the fumaratesalt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane ismono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane.12. The pharmaceutical composition of claim 10, further comprising oneor more further therapeutic agents as active ingredients.
 13. Thepharmaceutical composition of claim 10, comprising at least 90 weight %of the fumarate salt of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane,based on the weight of the composition.
 14. A pharmaceuticalcomposition, which comprises mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane asactive ingredient and at least one pharmaceutically acceptable carrier.15. The pharmaceutical composition of claim 14, further comprising oneor more further therapeutic agents as active ingredients.
 16. Thepharmaceutical composition of claim 14, comprising at least 90 weight %of mono-fumarate of(R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane,based on the weight of the composition.